Gene editing protein, corresponding gene editing system and application thereof
By developing new Cas proteins and fusion proteins with specific amino acid site mutations, the CRISPR-Cas composition was constructed, which solved the problem of the application of existing systems in gene editing, and achieved efficient target recognition and cleavage, satisfying the variety. Demand.
Patent Information
- Application Number
- CN202310532845.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2023-05-11
- Publication Date
- 2024-11-19
AI Technical Summary
The existing CRISPR/Cas system has differences in size, guide RNA and PAM structure in gene editing, which is difficult to meet the diverse application needs, and new Cas proteins and CRISPR-Cas systems are needed.
Provides a novel Cas protein whose amino acid sequence has specific homology and variants, including specific amino acid site mutations, forming derivative polypeptides or fusion proteins, and binding to functional domains, for the construction of CRISPR-Cas compositions and gene editing systems.
It realizes efficient identification and cleavage of targets, meets diverse application needs, provides a wider range of gene editing and detection methods, and improves editing efficiency and flexibility.
Smart Images

Figure BDA0004225035990000151 
Figure BDA0004225035990000291 
Figure BDA0004225035990000301
Abstract
Description
Technical Field
[0001] The present invention relates to the field of gene editing, and in particular, to a gene editing protein, a corresponding gene editing system and applications. Background Art
[0002] The Clustered regularly interspaced short palindromic repeats (CRISPR) system was formed by bacteria and archaea to defend against the DNA of invading phages. The most common of these is the CRISPR / Cas9 system, in which the Cas9 protein can process pre-crRNA into mature crRNA that binds to tracrRNA with the assistance of trans-encoded small RNA (tracrRNA). Later, people discovered that by artificially constructing a single-stranded chimeric guide RNA (gRNA) that simulates the crRNA-tracrRNA complex, it is possible to effectively mediate the recognition and cutting of the target by the Cas9 protein. The three bases adjacent to the 3′ end of the target must be in the form of 5′-NGG-3′, thus forming the PAM (protospacer adjacent motif) structure required for the Cas / crRNA complex to recognize the target.
[0003] However, the different CRISPR / Cas that exist currently have different advantages and disadvantages. For example, different Cas protein sizes, guide RNAs, and PAMs all differ.
[0004] Therefore, there is still a need to develop new Cas proteins and CRISPR-Cas systems to meet diverse application needs. Summary of the invention
[0005] The main purpose of the present invention is to provide a new Cas protein, its gene editing system and application to meet the above application needs. Based on this, the present invention also provides a new CRISPR-Cas composition and a gene editing method and nucleic acid detection method based on the system.
[0006] The first aspect of the present invention provides a Cas protein, wherein the protein is selected from the following group:
[0007] (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1;
[0008] (b) a polypeptide having ≥80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% homology (or identity) with the amino acid sequence of SEQ ID NO: 1, and the polypeptide has the biological function of SEQ ID NO: 1;
[0009] (c) A derivative polypeptide formed by replacing, deleting or adding one or more (preferably 1-20, more preferably 1-10, and more preferably 1-5) amino acid residues of any one of the amino acid sequences shown in SEQ ID NO: 1, and retaining the biological function of SEQ ID NO: 1.
[0010] The second aspect of the present invention provides a Cas protein variant, which is a non-natural protein, and the variant is mutated at one or more core amino acid sites associated with cleavage activity selected from the following group corresponding to SEQ ID NO: 1 in the wild-type Cas protein:
[0011] Aspartic acid (D) at position 592; and / or
[0012] Aspartic acid (D) at position 643; and / or
[0013] Glutamic acid (E) at position 820; and / or
[0014] Aspartic acid (D) at position 992.
[0015] In another preferred example, relative to the cleavage activity of the wild-type Cas protein, the Cas protein variant has reduced (e.g., reduced by 50%, 60%, 70%, 80%, 90%, 95% or more) or substantially lacking cleavage activity for the target sequence of the target molecule complementary to the guide RNA sequence.
[0016] In another preferred embodiment, the aspartic acid (D) at position 592 is mutated to any amino acid, preferably to the amino acid type shown in Table A, preferably to one or more amino acids selected from the following group: Ala (A), Val (V), Leu (L), Ile (I), preferably to Ala (A), Val (V), more preferably Ala (A).
[0017] In another preferred embodiment, the aspartic acid (D) at position 643 is mutated to any amino acid, preferably to the amino acid type shown in Table A, preferably to one or more amino acids selected from the following group: Ala (A), Val (V), Leu (L), Ile (I), preferably to Ala (A), Val (V), more preferably Ala (A).
[0018] In another preferred embodiment, the glutamic acid (E) at position 820 is mutated to any amino acid, preferably to the amino acid type shown in Table A, preferably to one or more amino acids selected from the following group: Ala (A), Val (V), Leu (L), Ile (I), preferably to Ala (A), Val (V), more preferably Ala (A).
[0019] In another preferred embodiment, the aspartic acid (D) at position 992 is mutated to any amino acid, preferably to the amino acid type shown in Table A, preferably to one or more amino acids selected from the following group: Ala (A), Val (V), Leu (L), Ile (I), preferably to Ala (A), Val (V), more preferably Ala (A).
[0020] In another preferred embodiment, the aspartic acid (D) at position 592 is mutated to alanine (A).
[0021] In another preferred embodiment, the aspartic acid (D) at position 643 is mutated to alanine (A).
[0022] In another preferred embodiment, the glutamic acid (E) at position 820 is mutated to alanine (A).
[0023] In another preferred embodiment, the aspartic acid (D) at position 992 is mutated to alanine (A).
[0024] In another preferred embodiment, the mutation is selected from the following group: D592A, D643A, E820A, D992A or a combination thereof.
[0025] In another preferred example, the amino acid sequence of the Cas protein variant is shown in any one of SEQ ID NO.47-50.
[0026] In another preferred embodiment, the Cas protein variant is a polypeptide having an amino acid sequence shown in any one of SEQ ID NO.47-50, an active fragment thereof, or a conservative variant polypeptide thereof.
[0027] In another preferred example, except for the mutations (such as positions 592, 643, 820 and / or 992), the remaining amino acid sequences of the Cas protein variant are identical or substantially identical to the sequence of the wild-type Cas protein.
[0028] In another preferred embodiment, the substantially identical is that there are at most 50 (preferably 1-20, more preferably 1-10, more preferably 1-5) amino acids that are different, wherein the differences include amino acid substitutions, deletions or additions, and the cleavage activity of the Cas protein variant is reduced.
[0029] In another preferred embodiment, the homology between the Cas protein variant and the wild-type Cas protein is at least 80%, preferably at least 85% or 90%, more preferably at least 95%, and most preferably at least 98% or 99%.
[0030] In another preferred embodiment, the Cas protein variant is selected from the following group:
[0031] (a) a polypeptide having an amino acid sequence as shown in any one of SEQ ID NOs. 47-50;
[0032] (b) A polypeptide derived from (a) with reduced cleavage activity, formed by substitution, deletion or addition of one or more (such as 2, 3, 4 or 5) amino acid residues in the amino acid sequence shown in any one of SEQ ID NOs. 47-50.
[0033] In another preferred embodiment, the derived polypeptide has a homology of at least 60% with the sequence shown in any one of SEQ ID NO.: 47-50, preferably at least 70%, more preferably at least 80%, and most preferably at least 90%, such as 95%, 97%, 99%.
[0034] In another preferred embodiment, the Cas protein variant is formed by mutation of the wild-type Cas protein.
[0035] The third aspect of the present invention provides a fusion protein comprising the Cas protein described in the first aspect of the present invention or the Cas protein variant described in the second aspect of the present invention; and one or more functional domains.
[0036] In another preferred embodiment, the functional domain is selected from a localization signal, a reporter protein, a Cas protein targeting portion, a DNA binding domain, an epitope tag, a transcription activation domain, a transcription repression domain, a nuclease, a deamination domain, a methylase, a demethylase, a transcription release factor, an HDAC, a cleavage active polypeptide, a ligase, an integrase, a transposase, a recombinase, a polymerase, and a base excision repair inhibitor (such as a uracil-DNA glycosylase inhibitor (UGI)).
[0037] In another preferred example, the functional domain includes one or more of the following enzymatic activities on the target sequence: methylase activity, demethylase activity, acetyltransferase activity, deacetylase activity, kinase activity, phosphatase activity, ubiquitin ligase activity, deubiquitinating activity, adenylation activity, deadenylation activity, SUMOylation activity, deSUMOylation activity, ribosylation activity, deribosylation activity, myristoylation activity, demyristoylation activity, glycosylation activity (e.g., from O-GlcNAc transferase) and deglycosylation activity.
[0038] In another preferred embodiment, the functional domain is selected from adenosine deaminase catalytic domain or cytidine deaminase catalytic domain.
[0039] In another preferred example, the adenosine deaminase catalytic domain or the cytidine deaminase catalytic domain includes one or more of ADAR1, ADAR2, APOBEC, AID or TAD.
[0040] In another preferred embodiment, the adenosine deaminase catalytic domain comprises an amino acid sequence that is at least 80%, 82%, 85%, 87%, 90%, 92%, 95%, 96%, 97%, 98% or 99% identical to the amino acid sequence shown in SEQ ID NO: 31 (selected from 005V1 deaminase in CN114634923 A, in which the amino acid sequence is SEQ ID NO: 2), and it retains the deamination activity of the amino acid sequence shown in SEQ ID NO: 31.
[0041] In another preferred embodiment, the amino acid sequence of the adenosine deaminase catalytic domain has amino acid additions, insertions, deletions and substitutions relative to the amino acid sequence shown in SEQ ID NO:31.
[0042] In another preferred embodiment, the adenosine deaminase catalytic domain includes a mutant of the amino acid sequence shown in SEQ ID NO: 31: Q148G+Q149M+P150R, named deaminase 005V1-10-3.
[0043] In another preferred embodiment, the functional domain is the full length or functional fragment of TadA8e.
[0044] In another preferred example, the localization signal includes a nuclear localization signal (NLS) and / or a nuclear export signal (NES).
[0045] In another preferred embodiment, the sequence of the nuclear localization signal is shown in any one of SEQ ID NOs: 38-45.
[0046] In another preferred embodiment, the sequence of the nuclear localization signal is located at, near or close to the end (eg, N-terminus or C-terminus) of the protein according to claim 1.
[0047] In another preferred embodiment, the nuclear export signal includes protein tyrosine kinase 2 (such as human protein tyrosine kinase 2).
[0048] In another preferred embodiment, the reporter protein includes glutathione-S-transferase (GST), horseradish peroxidase (HRP), chloramphenicol acetyltransferase (CAT), β-galactosidase, β-glucuronidase, and autofluorescent protein.
[0049] In another preferred embodiment, the autofluorescent protein includes green fluorescent protein (e.g., GFP, GFP-2, tagGFP, turboGFP, eGFP, CopGFP, AceGFP, etc.), HcRed, DsRed, cyan fluorescent protein (e.g., eCFP, Cerulean, CyPet, AmCyanl, etc.), yellow fluorescent protein (e.g., YFP, eYFP, Citrine, Venus, YPet, PhiYFP, etc.), blue fluorescent protein (e.g., eBFP, eBFP2, Azurite, mKalamal, GFPuv, Sapphire, T-sapphire).
[0050] In another preferred embodiment, the DNA binding domain includes methylation binding protein, LexADBD, and Gal4DBD.
[0051] In another preferred embodiment, the epitope tag includes a histidine tag, a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag, a thioredoxin tag, or a streptavidin tag.
[0052] In another preferred embodiment, the transcriptional activation domain includes VP64 and / or VPR.
[0053] In another preferred embodiment, the transcriptional repression domain includes KRAB and / or SID.
[0054] In another preferred embodiment, the nuclease includes FokI.
[0055] In another preferred embodiment, the cleavage active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity or a polypeptide having double-stranded DNA cleavage activity.
[0056] In another preferred embodiment, the ligase includes DNA ligase and / or RNA ligase.
[0057] In another preferred embodiment, the functional domain is connected to the N-terminus and / or C-terminus of the Cas protein or Cas protein variant.
[0058] In another preferred example, the functional domain is inserted between the N-terminus and C-terminus of the Cas protein or Cas protein variant.
[0059] In another preferred example, the one or more functional domains are optionally connected to the N-terminus and / or C-terminus of the Cas protein or Cas protein variant via a linker.
[0060] In another preferred example, the functional domain is inserted between the N-terminus and C-terminus of the Cas protein or Cas protein variant through a linker.
[0061] In another preferred embodiment, the fusion protein has the following structure from N-terminus to C-terminus:
[0062] Z1-Z2 (I); or
[0063] Z2-Z1 (II); or
[0064] Z3-Z1-Z4 (III);
[0065] wherein Z1 is cytosine deaminase or adenosine deaminase;
[0066] Z2 is the Cas protein according to claim 1 or the Cas protein variant according to claim 2;
[0067] Z3 is the N-terminal fragment of the Cas protein according to claim 1 or the Cas protein variant according to claim 2;
[0068] Z4 is the C-terminal fragment of the Cas protein according to claim 1 or the Cas protein variant according to claim 2;
[0069] Furthermore, each "-" is independently a bond or a linker.
[0070] In another preferred example, the fusion protein has the amino acid sequence shown in SEQ ID NO:46.
[0071] The fourth aspect of the present invention provides an isolated polynucleotide, which encodes the Cas protein described in the first aspect of the present invention or the Cas protein variant described in the second aspect of the present invention or the fusion protein described in the third aspect of the present invention.
[0072] In another preferred embodiment, the polynucleotide is selected from the following group:
[0073] (a) a polynucleotide whose sequence is shown in SEQ ID NO. 2 or 37;
[0074] (b) a polynucleotide having a nucleotide sequence homology of ≥70% (preferably ≥80%, more preferably ≥90%, more preferably ≥95%, and most preferably ≥99%) to the sequence shown in SEQ ID NO. 2 or 37, and encoding the polypeptide shown in SEQ ID NO. 1 or 46;
[0075] (c) A polynucleotide complementary to the polynucleotide described in any one of (a) to (b).
[0076] In another preferred embodiment, the isolated nucleotide comprises a humanized and optimized sequence.
[0077] In another preferred embodiment, the polynucleotide further contains auxiliary elements selected from the following groups on the flank of the ORF of the variant: a signal peptide, a secretory peptide, a tag sequence (such as 6His), or a combination thereof.
[0078] In another preferred embodiment, the polynucleotide is selected from the following group: genomic sequence, cDNA sequence, RNA sequence, or a combination thereof.
[0079] In another preferred example, the polynucleotide further comprises a promoter operably linked to the ORF sequence of the variant.
[0080] In another preferred embodiment, the promoter is selected from the following group: a constitutive promoter, a tissue-specific promoter, an inducible promoter, or a strong promoter.
[0081] In another preferred embodiment, the polynucleotide is a polynucleotide that is codon-optimized according to the codon preference of the host cell.
[0082] In another preferred embodiment, the host cell includes a prokaryotic cell or a eukaryotic cell.
[0083] In another preferred embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell or a mammalian cell (including human and non-human mammals).
[0084] In another preferred embodiment, the host cell is a prokaryotic cell, such as Escherichia coli.
[0085] In another preferred embodiment, the yeast cell is selected from yeast of one or more sources of the following group: Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis.
[0086] In another preferred embodiment, the host cell is selected from the following group: Escherichia coli, wheat germ cells, insect cells, SF9, Hela, HEK293, CHO, yeast cells, or a combination thereof.
[0087] The fifth aspect of the present invention provides an isolated nucleic acid molecule comprising or consisting of a sequence selected from the following:
[0088] (i) the sequence shown in SEQ ID NO: 5;
[0089] (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 5;
[0090] (iii) a sequence having at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% sequence identity to the sequence shown in SEQ ID NO:5;
[0091] (iv) a sequence that hybridizes to the sequence described in any one of (i) to (iii) under stringent conditions; or
[0092] (v) a complementary sequence of the sequence described in any one of (i) to (iii);
[0093] Furthermore, the sequence described in any one of (ii) to (v) substantially retains the biological function of the sequence from which it is derived;
[0094] For example, the isolated nucleic acid molecule is RNA;
[0095] For example, the isolated nucleic acid molecule comprises a direct repeat sequence in a CRISPR / Cas system.
[0096] In another preferred embodiment, the nucleic acid molecule comprises one or more stem loops or optimized secondary structures;
[0097] For example, the sequence of any of (ii)-(v) retains the secondary structure of the sequence from which it is derived.
[0098] In another preferred embodiment, the nucleic acid molecule comprises a sequence selected from the following, or consists of a sequence selected from the following:
[0099] (a) the nucleotide sequence shown in SEQ ID NO: 5;
[0100] (b) a sequence that hybridizes under stringent conditions to the sequence described in (a); or
[0101] (c) A complementary sequence to the nucleotide sequence shown in SEQ ID NO:5.
[0102] The sixth aspect of the present invention provides a guide RNA (gRNA), which includes a direct repeat (DR) sequence capable of binding to the Cas protein described in the first aspect of the present invention and a spacer sequence capable of targeting a target sequence.
[0103] The seventh aspect of the present invention provides a composite comprising:
[0104] (i) a protein component selected from the group consisting of the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, or a combination thereof; and
[0105] (ii) a nucleic acid component selected from the group consisting of the guide RNA described in the sixth aspect of the present invention, a nucleic acid encoding the guide RNA described in the sixth aspect of the present invention, a precursor RNA of the guide RNA described in the sixth aspect of the present invention, a precursor RNA nucleic acid encoding the guide RNA described in the sixth aspect of the present invention, or a combination thereof;
[0106] Wherein, the protein component and the nucleic acid component are combined with each other to form a complex.
[0107] In another preferred embodiment, the direct repeat (DR) sequence in the guide RNA (gRNA) is connected to the 3' end or the 5' end of the nucleic acid molecule.
[0108] In another preferred embodiment, the spacer sequence in the guide RNA (gRNA) comprises a complementary sequence to the target sequence.
[0109] The eighth aspect of the present invention provides a vector comprising the polynucleotide described in the fourth aspect of the present invention or the nucleic acid molecule described in the fifth aspect of the present invention.
[0110] In another preferred embodiment, the vector comprises:
[0111] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the Cas protein of claim 1, or a nucleotide sequence encoding the Cas protein variant of claim 2, or a nucleotide sequence encoding the fusion protein of claim 3; and
[0112] (2) a second regulatory element, the second regulatory element being operably linked to a nucleotide sequence encoding a guide RNA, the guide RNA comprising:
[0113] (a) a spacer sequence capable of hybridizing to the target sequence, and
[0114] (b) a direct repeat (DR) sequence, which is connected to the spacer sequence and can guide the Cas protein according to claim 1 or the Cas protein variant according to claim 2 to bind to the guide RNA to form the complex according to claim 7 targeting the target sequence.
[0115] In another preferred example, the first regulatory element and the second regulatory element are located on the same or different vectors.
[0116] In another preferred embodiment, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter.
[0117] In another preferred embodiment, the vector comprises one or more promoters, which are operably connected to the nucleic acid sequence, enhancer, transcription termination signal, polyadenylation sequence, replication origin, selective marker, nucleic acid restriction site, and / or homologous recombination site.
[0118] In another preferred embodiment, the vector includes a plasmid or a viral vector.
[0119] In another preferred embodiment, the viral vector is selected from the following group: adeno-associated virus (AAV), adenovirus, lentivirus, retrovirus, herpes virus, SV40, poxvirus, or a combination thereof.
[0120] In another preferred embodiment, the vector includes a cloning vector, a transformation vector, an expression vector, a shuttle vector, an integration vector, and a multifunctional vector.
[0121] A ninth aspect of the present invention provides a CRISPR-Cas composition comprising:
[0122] (i) a first component selected from the group consisting of the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, a nucleotide sequence encoding the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention, and any combination thereof; and
[0123] (ii) a second component, wherein the second component comprises one or more guide RNAs according to the sixth aspect of the present invention, or a nucleotide sequence encoding the one or more guide RNAs according to the sixth aspect of the present invention;
[0124] The guide RNA is capable of forming a complex with the protein, protein variant or fusion protein described in (i).
[0125] In another preferred embodiment, the guide RNA comprises a direct repeat sequence and a spacer sequence from the 5' to the 3' direction, and the spacer sequence can hybridize with the target sequence.
[0126] In another preferred embodiment, the direct repeat sequence is the nucleic acid molecule defined in the fifth aspect of the present invention.
[0127] In another preferred embodiment, the composition further comprises a pharmaceutically acceptable carrier.
[0128] In another preferred embodiment, the composition comprises a pharmaceutical composition.
[0129] In another preferred embodiment, the dosage form of the composition is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.
[0130] In another preferred embodiment, the composition is in the form of a liquid preparation.
[0131] In another preferred embodiment, the composition is in the form of an injection.
[0132] In another preferred embodiment, the composition is a cell preparation.
[0133] The tenth aspect of the present invention provides a CRISPR-Cas system, comprising one or more vectors, wherein the one or more vectors comprise:
[0134] (i) a first nucleic acid, which is a nucleotide sequence encoding the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention; optionally, the first nucleic acid is operably linked to a first regulatory element; and
[0135] (ii) a second nucleic acid encoding a nucleotide sequence comprising the guide RNA according to the sixth aspect of the invention; optionally, the second nucleic acid is operably linked to a second regulatory element;
[0136] in:
[0137] The first nucleic acid and the second nucleic acid are present on the same or different vectors;
[0138] The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).
[0139] In another preferred embodiment, the vector includes a plasmid or a viral vector.
[0140] In another preferred embodiment, the guide RNA includes a spacer sequence capable of hybridizing with a target sequence; and a direct repeat (DR) sequence connected to the spacer sequence and capable of guiding the protein to bind to the guide RNA, thereby forming a CRISPR-Cas composition or complex targeting the target sequence.
[0141] In another preferred embodiment, the guide RNA includes unmodified and modified guide RNA.
[0142] In another preferred embodiment, the modified guide RNA includes chemical modification of the bases.
[0143] In another preferred embodiment, the chemical modification includes methylation modification, methoxy modification, fluorination modification or thio modification.
[0144] In another preferred embodiment, the directly repeated sequence is the nucleic acid molecule defined in claim 5.
[0145] In another preferred embodiment, the first regulatory element and / or the second regulatory element is a promoter, such as an inducible promoter.
[0146] In another preferred embodiment, at least one component in the composition is non-naturally occurring or modified.
[0147] In another preferred embodiment, the spacer sequence is connected to the 3' end of the direct repeat (DR) sequence.
[0148] In another preferred example, the spacer sequence comprises a complementary sequence to the target sequence.
[0149] In another preferred embodiment, when the target sequence is DNA, the target sequence is located at the 3' end of the protospacer adjacent motif (PAM), and the PAM has a sequence represented by 5'-PAM being TTN, and N is A, T, C or G.
[0150] In another preferred embodiment, the target sequence is a DNA from a prokaryotic cell or a eukaryotic cell, or a DNA sequence formed based on RNA reverse transcription; or, the target sequence is a non-naturally occurring DNA, or a DNA sequence formed based on RNA reverse transcription.
[0151] In another preferred example, the target sequence includes a cDNA sequence.
[0152] In another preferred embodiment, the target sequence includes single-stranded DNA and double-stranded DNA sequences.
[0153] In another preferred embodiment, the target sequence exists in cells.
[0154] In another preferred embodiment, the target sequence is present in the cell nucleus or cytoplasm (eg, organelle).
[0155] In another preferred embodiment, the cell is a eukaryotic cell.
[0156] In another preferred embodiment, the cell is a prokaryotic cell.
[0157] In another preferred embodiment, the target sequence exists outside the cell.
[0158] In another preferred embodiment, the Cas protein in the first aspect of the present invention is connected to one or more NLS sequences, or the fusion protein contains one or more NLS sequences.
[0159] In another preferred embodiment, the NLS sequence is connected to the N-terminus or C-terminus of the Cas protein described in the first aspect of the present invention.
[0160] In another preferred embodiment, the NLS sequence is fused to the N-terminus or C-terminus of the Cas protein described in the first aspect of the present invention.
[0161] The eleventh aspect of the present invention provides a kit comprising one or more components selected from the following: the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention.
[0162] In another preferred embodiment, the kit further comprises a label or instructions.
[0163] In another preferred embodiment, the kit is used for one or more of gene or genome editing, disease treatment, target gene targeting, and cutting of target genes or non-target genes.
[0164] The twelfth aspect of the present invention provides a delivery composition comprising a delivery vector and one or more selected from the following: the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention.
[0165] In another preferred embodiment, the delivery vehicle is a particle.
[0166] In another preferred embodiment, the delivery vector is selected from lipid particles, sugar particles, metal particles, protein particles, liposomes, exosomes, microvesicles, gene guns or viral vectors (e.g., replication-defective retroviruses, lentiviruses, adenoviruses or adeno-associated viruses).
[0167] The thirteenth aspect of the present invention provides a host cell, comprising the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the nucleic acid molecule described in the fifth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the composition described in the ninth aspect of the present invention, the system described in the tenth aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention.
[0168] In another preferred embodiment, the host cell is a eukaryotic cell, such as a yeast cell, a plant cell or a mammalian cell (including human and non-human mammals).
[0169] In another preferred embodiment, the host cell is a prokaryotic cell, such as Escherichia coli.
[0170] In another preferred embodiment, the yeast cell is selected from yeast of one or more sources of the following group: Pichia pastoris, Kluyveromyces, or a combination thereof; preferably, the yeast cell includes: Kluyveromyces, more preferably Kluyveromyces marxianus, and / or Kluyveromyces lactis.
[0171] In another preferred embodiment, the host cell is selected from the following group: Escherichia coli, wheat germ cells, insect cells, SF9, Hela, HEK293, CHO, yeast cells, or a combination thereof.
[0172] The fourteenth aspect of the present invention provides an enzyme preparation, which includes the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the complex described in the seventh aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention or the delivery composition described in the twelfth aspect of the present invention.
[0173] In another preferred embodiment, the enzyme preparation includes an injection and / or a lyophilized preparation.
[0174] A fifteenth aspect of the present invention provides a medicine kit, comprising:
[0175] A first container, and the complex described in the seventh aspect of the present invention, the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention located in the first container, or a drug containing the complex described in the seventh aspect of the present invention, the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention.
[0176] In another preferred embodiment, the drug in the first container is a single preparation containing the complex described in the seventh aspect of the present invention, the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention.
[0177] In another preferred embodiment, the dosage form of the drug is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.
[0178] In another preferred embodiment, the dosage form of the drug is an oral dosage form or an injection dosage form.
[0179] In another preferred embodiment, the medicine kit further contains instructions.
[0180] A sixteenth aspect of the present invention provides a medicine kit, comprising:
[0181] (a1) a first container, and the Cas protein of the first aspect of the present invention, or the Cas protein variant of the second aspect of the present invention, or the fusion protein of the third aspect of the present invention, or a gene encoding the same or an expression vector thereof, or a drug containing the Cas protein of the first aspect of the present invention, or the Cas protein variant of the second aspect of the present invention, or the fusion protein of the third aspect of the present invention, or a gene encoding the same or an expression vector thereof, located in the first container;
[0182] (b1) an optional second container, and the guide RNA or its expression vector according to the sixth aspect of the present invention, or a drug containing the guide RNA or its expression vector according to the sixth aspect of the present invention, located in the second container.
[0183] In another preferred embodiment, the first container and the second container are different containers.
[0184] In another preferred embodiment, the drug in the first container is a single preparation containing the Cas protein described in the first aspect of the present invention, or the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention, or its encoding gene or its expression vector.
[0185] In another preferred embodiment, the drug in the second container is a single preparation containing the guide RNA or its expression vector described in the sixth aspect of the present invention.
[0186] In another preferred embodiment, the dosage form of the drug is selected from the following group: a lyophilized preparation, a liquid preparation, or a combination thereof.
[0187] In another preferred embodiment, the dosage form of the drug is an oral dosage form or an injection dosage form.
[0188] In another preferred embodiment, the medicine kit further contains instructions.
[0189] The seventeenth aspect of the present invention provides a method for targeting and editing a target gene or cutting a target gene, comprising: contacting the Cas protein described in the first aspect of the present invention, or the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention, or the complex described in the seventh aspect of the present invention, or the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention, or the drug kit described in the fifteenth aspect of the present invention or the sixteenth aspect of the present invention with the target gene, or delivering it to a cell containing the target gene, and the target sequence is present in the target gene.
[0190] In another preferred embodiment, the target gene exists in cells.
[0191] In another preferred embodiment, the cell is a prokaryotic cell.
[0192] In another preferred embodiment, the cell is a eukaryotic cell, such as a mammalian cell (eg, a human cell) or a plant cell.
[0193] In another preferred embodiment, the target gene exists in a nucleic acid molecule (eg, a plasmid) in vitro.
[0194] In another preferred example, the editing of the target gene or the cutting of the target gene includes the break of the target sequence, such as a double-strand break of DNA or a single-strand break of RNA, or the insertion of an exogenous nucleic acid into the break.
[0195] In another preferred embodiment, the target gene includes DNA.
[0196] In another preferred embodiment, the DNA includes single-stranded DNA and double-stranded DNA.
[0197] The eighteenth aspect of the present invention provides a method for inducing a change in a cell state, the method comprising contacting the Cas protein described in the first aspect of the present invention, or the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention, or the complex described in the seventh aspect of the present invention, or the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention, or the drug kit described in the fifteenth aspect of the present invention or the sixteenth aspect of the present invention with a target gene in a cell.
[0198] The nineteenth aspect of the present invention provides a method for changing the expression of a gene product, comprising: contacting the Cas protein described in the first aspect of the present invention, or the Cas protein variant described in the second aspect of the present invention, or the fusion protein described in the third aspect of the present invention, or the complex described in the seventh aspect of the present invention, or the composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention, or the drug kit described in the fifteenth aspect of the present invention or the sixteenth aspect of the present invention with a nucleic acid molecule encoding the gene product, or delivering it to a cell containing the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.
[0199] In another preferred embodiment, the nucleic acid molecule is present in an in vitro nucleic acid molecule (eg, a plasmid).
[0200] In another preferred embodiment, the expression of the gene product is altered (eg, enhanced or decreased).
[0201] In another preferred embodiment, the gene product is a protein.
[0202] In another preferred embodiment, the protein, fusion protein, polynucleotide, isolated nucleic acid molecule, complex, vector or composition is contained in a delivery vehicle.
[0203] In another preferred embodiment, the delivery vector is selected from lipid particles, sugar particles, metal particles, protein particles, liposomes, exosomes, viral vectors (such as replication-defective retroviruses, lentiviruses, adenoviruses or adeno-associated viruses).
[0204] In another preferred embodiment, the method is used to modify cells, cell lines or organisms by changing one or more target sequences in a target gene or a nucleic acid molecule encoding a target gene product.
[0205] The twentieth aspect of the present invention provides a cell or its progeny obtained by the method described in any one of the seventeenth to nineteenth aspects of the present invention, wherein the cell comprises a modification that is not present in its wild type.
[0206] The twenty-first aspect of the present invention provides a cell product of the cell or its progeny described in the twentieth aspect of the present invention.
[0207] The twenty-second aspect of the present invention provides an in vitro, ex vivo or in vivo cell or cell line or their progeny, wherein the cell or cell line or their progeny comprises: the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention.
[0208] In another preferred embodiment, the cell is a prokaryotic cell.
[0209] In another preferred embodiment, the cell is a eukaryotic cell, such as a mammalian cell (eg, a human cell) or a plant cell.
[0210] In another preferred embodiment, the cells are stem cells or stem cell lines.
[0211] The twenty-third aspect of the present invention provides the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the nucleic acid molecule described in the fifth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the kit described in the eleventh aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention, or the drug kit described in the fifteenth aspect of the present invention or the sixteenth aspect of the present invention, for the preparation of a drug or preparation, wherein the drug or preparation is used for nucleic acid editing (e.g., gene or genome editing).
[0212] In another preferred embodiment, the gene or genome editing includes modifying genes, knocking out genes, changing the expression of gene products, repairing mutations, and / or inserting polynucleotides.
[0213] The twenty-fourth aspect of the present invention provides the Cas protein described in the first aspect of the present invention, the protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, the polynucleotide described in the fourth aspect of the present invention, the complex described in the seventh aspect of the present invention, the vector described in the eighth aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, or the kit described in the eleventh aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention, or the drug kit described in the fifteenth aspect of the present invention or the sixteenth aspect of the present invention, for the preparation of a drug or preparation, wherein the drug or preparation is used for one or more selected from the following group:
[0214] (i) ex vivo gene or genome editing;
[0215] (ii) Detection of single-stranded DNA in vitro;
[0216] (iii) editing a target sequence in a target locus to modify an organism or non-human organism;
[0217] (iv) treating a disorder caused by a defect in the target sequence in the target locus;
[0218] (v) treating a condition or disease in a subject in need thereof.
[0219] In another preferred embodiment, the disease or illness includes cancer, infectious disease, neurological disease, ophthalmic disease, hearing disease.
[0220] In another preferred embodiment, the disease or condition includes cystic fibrosis, Duchenne muscular dystrophy (DMD), Becker muscular dystrophy, alpha-1-antitrypsin deficiency, Pompe disease (glycogen storage disease type II), myotonic dystrophy, Huntington's disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, hereditary chronic kidney disease, sickle cell disease, beta thalassemia, frontotemporal dementia, Leber's congenital amaurosis, hyperlipidemia, hypercholesterolemia, transthyretin amyloidosis, retinal Diseases, macular degeneration, Wilms tumor, Ewing sarcoma, neuroendocrine tumors, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, bile duct cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, and urinary bladder cancer.
[0221] In another preferred embodiment, the disorder or disease is caused by a pathogenic point mutation.
[0222] The twenty-fifth aspect of the present invention provides a method for detecting whether a target nucleic acid molecule is present in a sample, characterized in that the method comprises contacting the sample with the Cas protein described in the first aspect of the present invention, the Cas protein variant described in the second aspect of the present invention, the fusion protein described in the third aspect of the present invention, or the complex described in the seventh aspect of the present invention, the CRISPR-Cas composition described in the ninth aspect of the present invention, or the system described in the tenth aspect of the present invention, the kit described in the eleventh aspect of the present invention, or the delivery composition described in the twelfth aspect of the present invention, or the enzyme preparation described in the fourteenth aspect of the present invention and a non-target sequence, detecting a detectable signal generated by the cutting of the non-target sequence, thereby detecting the target nucleic acid molecule, and the non-target sequence does not hybridize with the guide RNA.
[0223] In another preferred example, if the non-target sequence is cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, it indicates that the target nucleic acid molecule is present in the sample; and if the non-target sequence is not cleaved by a protein in the complex or CRISPR-Cas composition or system or delivery composition, it indicates that the target nucleic acid molecule is not present in the sample.
[0224] In another preferred embodiment, the target nucleic acid molecule is a target DNA.
[0225] In another preferred embodiment, the target DNA includes DNA formed based on RNA reverse transcription.
[0226] In another preferred embodiment, the target DNA includes cDNA.
[0227] In another preferred embodiment, the target DNA is selected from the following group: single-stranded DNA, double-stranded DNA, or a combination thereof.
[0228] It should be understood that within the scope of the present invention, the above-mentioned technical features of the present invention and the technical features specifically described below (such as embodiments) can be combined with each other to form a new or preferred technical solution. Due to space limitations, they will not be described one by one here. BRIEF DESCRIPTION OF THE DRAWINGS
[0229] Figure 1 The CasY7 recombinant expression plasmid ( Figure 1 A) and LbCpf1 recombinant expression plasmid map ( Figure 1 B).
[0230] Figure 2 The secondary structure prediction of the direct repeat (DR) sequence corresponding to CasY7 is shown.
[0231] Figure 3 The Target plasmid map is shown.
[0232] Figure 4 Shown is a comparison of the editing efficiency of CasY7 and LbCpf1 in Escherichia coli.
[0233] Figure 5 The PHK09T plasmid map is shown.
[0234] Figure 6 Shown is a comparison of the editing efficiency of CasY7 and LbCpf1 in HEK293T cells.
[0235] Figure 7 Four mutants of CasY7 are shown, which abolished the catalytic activity (cleavage activity) compared to the wild-type CasY7 protein.
[0236] Figure 8 The activity detection of dCasY7 in base editing is shown, wherein, Figure 8 A shows the single-base editing (A>G) efficiency of the base editor composed of dCasY7 at sites A2, A4, A13, and A15-A17; Figure 8 B shows the single-base editing (A>G) efficiency of the base editor composed of dCasY7 at A7, A13, and A20. DETAILED DESCRIPTION
[0237] After extensive and in-depth research, the inventors unexpectedly discovered a new Cas protein for the first time. The Cas protein of the present invention has very good gene editing activity, can effectively edit or cut the target gene, and can effectively treat the disease or disease of a subject in need (for example, a disease or disease caused by a pathogenic point mutation, including cystic fibrosis, progressive pseudohypertrophic muscular dystrophy (Duchenne muscular dystrophy, DMD), Becker muscular dystrophy, α-1-antitrypsin deficiency, Pompe disease (glycogen storage disease type II), myotonic dystrophy, Huntington's disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, hereditary chronic kidney disease, sickle cell disease, β-thalassemia, frontotemporal dementia, Leber's congenital amaurosis, hyperlipidemia, hypercholesterolemia, transthyretin amyloidosis, primary hyperoxaluria (PH1), pneumonia, hepatitis, Hereditary angioedema (HAE), retinal diseases, macular degeneration, Wilms tumor, Ewing sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, bile duct cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma and urinary bladder cancer); Compared with the Cas enzyme disclosed in the prior art, the editing efficiency of the Cas protein of the present invention has advantages, which provides more choices for base editing tools; the base editor constructed by the Cas enzyme disclosed in the present invention can effectively perform base editing and has potential application prospects. On this basis, the inventors have completed the present invention.
[0238] the term
[0239] The following examples are only used to describe the present invention, but not to limit the present invention. Unless otherwise specified, the experiments and methods described in the examples are basically carried out according to conventional methods well known in the art and described in various references.
[0240] In addition, if the specific conditions are not specified in the examples, they are carried out according to the conventional conditions or the conditions recommended by the manufacturer. If the manufacturer is not specified in the reagents or instruments used, they are all conventional products that can be obtained commercially. It is known to those skilled in the art that the embodiments describe the present invention by way of example and are not intended to limit the scope of the present invention. All public cases and other references mentioned herein are incorporated herein by reference in their entirety.
[0241] In order to more easily understand the present disclosure, some terms are first defined. As used in this application, unless otherwise expressly provided herein, each of the following terms should have the meaning given below. Other definitions are set forth throughout the application.
[0242] The term "about" can refer to a value or composition that is within an acceptable error range for a particular value or composition as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined. For example, as used herein, the expression "about 100" includes all values between 99 and 101 (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0243] As used herein, the term "comprising" or "including (comprising)" may be open, semi-closed and closed. In other words, the term also includes "consisting essentially of" or "consisting of".
[0244] Sequence identity (or homology) is determined by comparing two aligned sequences along a predetermined comparison window (which can be 50%, 60%, 70%, 80%, 90%, 95% or 100% of the length of the reference nucleotide sequence or protein) and determining the number of positions at which identical residues occur. Typically, this is expressed as a percentage. The measurement of sequence identity of nucleotide sequences is a method well known to those skilled in the art.
[0245] Cas proteins
[0246] In the present invention, Cas protein, Cas enzyme, and Cas effector protein can be used interchangeably. Cas protein is taken in the broadest sense, including wild-type Cas protein, its derivatives or variants, analogs, and functional fragments thereof such as oligonucleotide binding fragments.
[0247] The term "wild type" has the meaning generally understood by those skilled in the art, which refers to the typical form of an organism, strain, gene, protein, or the characteristics that distinguish it from mutant or variant forms when it exists in nature, which can be isolated from a source in nature and has not been intentionally modified by man.
[0248] The terms "variant", "derivative" and "analog" refer to polypeptides that substantially retain the function or activity of the Cas protein of the present invention.
[0249] Typically, the derivatization of a protein does not adversely affect the desired activity of the protein (e.g., activity binding to a guide RNA, endonuclease activity, activity binding to and cutting a specific site of a target sequence under the guidance of a guide RNA), that is, the derivative of the protein has the same activity as the protein. A modified form of a "derivative" includes one or more amino acids of the protein that may be deleted, inserted, modified and / or substituted. The terms "non-naturally occurring" or "engineered" are used interchangeably and indicate artificial involvement.
[0250] In one aspect, the present invention provides a Cas protein comprising an amino acid sequence having at least 80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% identity with the amino acid sequence of SEQ ID NO.1, and substantially retains the biological function of the sequence from which it is derived;
[0251] In one embodiment, the amino acid sequence of the Cas protein has one or more amino acid substitutions, deletions or additions compared to the amino acid sequence of SEQ ID NO.1, and substantially retains the biological function of the sequence from which it is derived;
[0252] In one embodiment, the Cas protein comprises the amino acid sequence shown in SEQ ID NO.1;
[0253] Or a sequence having one or more amino acid substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO.1; or a sequence having at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% amino acid sequence identity with the amino acid sequence shown in SEQ ID NO.1;
[0254] In one embodiment, the protein has the amino acid sequence shown in SEQ ID NO.1.
[0255] It is clear to those skilled in the art that the structure of a protein can be changed without adversely affecting its activity and functionality, for example, by introducing one or more conservative amino acid substitutions into the amino acid sequence of the protein without adversely affecting the activity and / or three-dimensional structure of the protein molecule.
[0256] Those skilled in the art are aware of examples and embodiments of conservative amino acid substitutions. Specifically, the amino acid residue can be substituted with another amino acid residue belonging to the same group as the site to be substituted, i.e., another non-polar amino acid residue can be substituted with a non-polar amino acid residue, another polar non-charged amino acid residue can be substituted with a polar uncharged amino acid residue, another basic amino acid residue can be substituted with a basic amino acid residue, and another acidic amino acid residue can be substituted with an acidic amino acid residue. Such substituted amino acid residues may or may not be encoded by a genetic code. As long as the substitution does not result in the inactivation of the biological activity of the protein, the conservative substitution of one amino acid being substituted by other amino acids belonging to the same group falls within the scope of the present invention. Therefore, the protein of the present invention can include one or more conservative substitutions in the amino acid sequence, and these conservative substitutions are preferably produced by substitution according to Table A. In addition, the present invention also encompasses proteins that also include one or more other non-conservative substitutions, as long as the non-conservative substitutions do not significantly affect the desired function and biological activity of the protein of the present invention.
[0257] Conservative amino acid substitutions can be performed at one or more predicted non-essential amino acid residues. "Non-essential" amino acid residues are amino acid residues that can be changed (deleted, substituted or replaced) without changing biological activity, while "essential" amino acid residues are required for biological activity. "Conservative amino acid substitutions" are substitutions in which amino acid residues are replaced by amino acid residues with similar side chains. Amino acid substitutions can be performed in non-conserved regions of Cas enzymes. In general, such substitutions are not performed on conserved amino acid residues, or on amino acid residues located within conserved motifs, where such residues are required for protein activity. However, it will be appreciated by those skilled in the art that functional variants may have fewer conservative or non-conservative changes in conserved regions.
[0258] Table A
[0259]
[0260] It is known to those skilled in the art that one or more amino acid residues can be changed (replaced, deleted, truncated or inserted) from the N and / or C terminus of a protein while still retaining its functional activity. Therefore, proteins that have changed one or more amino acid residues from the N and / or C terminus of the Cas protein of the present invention while retaining its desired functional activity are also within the scope of the present invention. These changes may include changes introduced by modern molecular methods such as PCR, which includes PCR amplification of a protein coding sequence by means of an amino acid coding sequence included in the oligonucleotides used in the PCR amplification to change or extend the PCR amplification.
[0261] It will be appreciated that proteins can be altered in a variety of ways, including amino acid substitutions, deletions, truncations, and insertions, and methods for such manipulations are generally known to those skilled in the art.
[0262] For example, amino acid sequence variants of Cas proteins can be prepared by mutation of DNA. It can also be accomplished by other forms of mutagenesis and / or by directed evolution, for example, using known mutagenesis, recombination and / or shuffling methods, combined with relevant screening methods, to perform one or more amino acid substitutions; or one to more amino acid deletions and / or one to more amino acid insertions.
[0263] Those skilled in the art will appreciate that these minor amino acid changes in the Cas proteins of the present invention can occur (e.g., naturally occurring mutations) or be produced (e.g., using r-DNA technology) without loss of protein function or activity. If these mutations occur in the catalytic domain, active site, or other functional domain of the protein, the properties of the polypeptide may be changed, but the polypeptide may retain its activity. If the mutations present are not close to the catalytic domain, active site, or other functional domain, it can be expected that the impact will be small.
[0264] Those skilled in the art can identify the essential amino acids of the Cas protein according to methods known in the art, such as site-directed mutagenesis or protein evolution or analysis of bioinformatics systems. The catalytic domain, active site or other functional domain of the protein can also be determined by physical analysis of the structure, such as by the following techniques: such as nuclear magnetic resonance, crystallography, electron diffraction or photoaffinity labeling, combined with mutations of amino acids at putative key sites.
[0265] Orthologue (ortholog)
[0266] As used herein, the term "orthologue" has the meaning commonly understood by those skilled in the art. As a further guide, an "orthologue" of a protein as described herein refers to a protein belonging to a different species that performs the same or similar function as its orthologue.
[0267] The nucleic acid cleavage disclosed herein includes: DNA or RNA breakage in the target nucleic acid produced by the Cas protein (Cis cleavage), DNA or RNA breakage in the side branch nucleic acid substrate (single-stranded nucleic acid substrate) caused by the Cas protein side cutting activity (i.e., non-specific or non-targeted, Trans cleavage). In some embodiments, the cleavage is a double-stranded DNA break. In some embodiments, the cleavage is a single-stranded DNA break or a single-stranded RNA break.
[0268] Trans cutting refers to that in certain environments, the activated Cas12 family protein remains active after binding to the target sequence, and continues to non-specifically cut non-target oligonucleotides. The side cutting activity can detect the presence of specific target oligonucleotides using the Cas system. For example, the Cas12i system is engineered to non-specifically cut ssDNA or transcripts. Side cutting activity is used for a highly sensitive and specific nucleic acid detection platform called SHERLOCK, which can be used for many clinical diagnoses (Gootenberg, JS et al., Nucleic acid detection with CRISPR-Cas13a / C2c2. Science 356, 438-442 (2017)).
[0269] Fusion Protein
[0270] In one aspect, the present invention provides a fusion protein, comprising the Cas protein described in any one of the foregoing and one or more functional domains.
[0271] In one embodiment, the functional domain includes one or more of a localization signal, a reporter protein, a Cas protein targeting portion, a DNA binding domain, an epitope tag, a transcription activation domain, a transcription repression domain, a nuclease, a deamination domain, a methylase, a demethylase, a transcription release factor, an HDAC, a cleavage active polypeptide, and a ligase;
[0272] In one embodiment, "methylase", exemplary, such as HhaI DNA m5c-methyltransferase (M.HhaI), DNA methyltransferase 1 (DNMT1), DNA methyltransferase 3a (DNMT3a), DNA methyltransferase 3b (DNMT3b), METI, DRM3, ZMET2, CMT1, CMT2, etc.
[0273] "Demethylase" refers to an enzyme that removes methyl (CH3-) groups from nucleic acids, proteins (e.g., histones) and other molecules. Demethylases are important in epigenetic modification mechanisms. Demethylase proteins change the transcriptional regulation of the genome by controlling the methylation levels that occur on DNA and histones, and then regulate the chromatin state at specific loci in the organism, such as TET1 (ten-eleven translocation 1), ten-eleven translocation (TET) dioxygenase 1 (TET1CD), DME, DML1, DML2, ROS1, etc.
[0274] In another preferred embodiment, the transcriptional release factor, for example, is eukaryotic release factor 1 (ERF1) activity or eukaryotic release factor 3 (ERF3).
[0275] In one embodiment, the functional domain is selected from an adenosine deaminase catalytic domain or a cytidine deaminase catalytic domain.
[0276] In one embodiment, the localization signal comprises a nuclear localization signal and / or a nuclear export signal;
[0277] Preferably, the nuclear export signal comprises human protein tyrosine kinase 2;
[0278] Preferably, the reporter protein comprises one or more of glutathione-S-transferase, horseradish peroxidase, chloramphenicol acetyltransferase, β-galactosidase, β-glucuronidase or autofluorescent protein;
[0279] Preferably, the autofluorescent protein includes one or more of green fluorescent protein, HcRed, DsRed, cyan fluorescent protein, yellow fluorescent protein or blue fluorescent protein;
[0280] Preferably, the DNA binding domain comprises one or more of methylation binding protein, LexADBD or Gal4DBD;
[0281] Preferably, the epitope tag comprises one or more of a histidine tag, a V5 tag, a FLAG tag, an influenza virus hemagglutinin tag, a Myc tag, a VSV-G tag or a thioredoxin tag;
[0282] Preferably, the transcriptional activation domain comprises VP64 and / or VPR;
[0283] Preferably, the transcriptional repression domain comprises KRAB and / or SID;
[0284] Preferably, the nuclease comprises FokI;
[0285] Preferably, the deamination domain comprises one or more of ADAR1, ADAR2, APOBEC, AID or TAD;
[0286] Preferably, the cleavage active polypeptide includes a polypeptide having single-stranded RNA cleavage activity, a polypeptide having double-stranded RNA cleavage activity, a polypeptide having single-stranded DNA cleavage activity or a polypeptide having double-stranded DNA cleavage activity;
[0287] Preferably, the ligase comprises DNA ligase and / or RNA ligase.
[0288] In one embodiment, the functional domain is the full length or a functional fragment of TadA8e.
[0289] Polynucleotide
[0290] In one aspect, the present invention provides a polynucleotide, which is a polynucleotide sequence encoding the Cas protein, or a polynucleotide sequence encoding the aforementioned fusion protein.
[0291] In one embodiment, the polynucleotide is a DNA molecule that is codon-optimized according to the codon preference of the host cell;
[0292] The optimization described in the present disclosure may require mutations in the nucleotide sequence of the coded protein (e.g., the Cas protein of the present disclosure) to simulate the codon preference of the expected host organism or cell when encoding the same protein at the same time. Therefore, the codon can be changed, but the encoded protein remains unchanged. For example, if the expected target cell is a human cell, a nucleotide sequence of the coded protein optimized by human codons can be used. As another non-limiting embodiment, if the expected host cell is an animal cell (e.g., a mouse cell, an insect cell), a nucleotide sequence of the coded protein optimized by the animal codon can be generated. As another non-limiting embodiment, if the expected host cell is a plant cell, a nucleotide sequence of the coded protein optimized by plant codons can be generated.
[0293] A selection list of codons is readily available, for example, the "Codon Usage Database" available at www.kazusa.or.jp / codon. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant or its fusion protein, the nucleotide sequence being codon-optimized for expression in eukaryotic cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant or its fusion protein, the nucleotide sequence being codon-optimized for expression in animal cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant or its fusion protein, the nucleotide sequence being codon-optimized for expression in fungal cells. In some cases, the nucleic acid of the present disclosure comprises a nucleotide sequence encoding CasY7 or its variant or its fusion protein, the nucleotide sequence being codon-optimized for expression in plant cells.
[0294] In one embodiment, the host cell comprises a prokaryotic cell or a eukaryotic cell;
[0295] In one embodiment, the DNA molecule comprises nucleotides having more than 70%, preferably more than 90%, more preferably more than 95%, further preferably 99%, and further preferably 100% identity with the nucleotide sequence of any one of SEQ ID NO.2 or 37.
[0296] CRISPR system
[0297] The terms “Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-CRISPR-associated (Cas) (CRISPR-Cas) system” or “CRISPR system” are used interchangeably and have the meaning commonly understood by those skilled in the art, which generally includes transcription products or other elements related to the expression of CRISPR-associated (“Cas”) genes, or transcription products or other elements capable of directing the activity of the Cas genes.
[0298] CRISPR-Cas Composition
[0299] In one aspect, the present invention also provides a CRISPR-Cas composition, comprising:
[0300] (1) Protein component: the aforementioned Cas protein, or the aforementioned fusion protein; or a nucleic acid molecule encoding the Cas protein or the fusion protein;
[0301] (2) RNA component: guide RNA, or one or more nucleic acids encoding the guide RNA, or a precursor RNA of the guide RNA, or a nucleic acid encoding a precursor RNA of the guide RNA;
[0302] The protein component and the nucleic acid component are combined with each other to form a complex.
[0303] In one embodiment, the composition is an activated CRISPR complex, and the activated CRISPR complex further comprises: a target sequence of a target nucleic acid bound to the guide RNA.
[0304] In one embodiment, the CRISPR-Cas composition comprises one or more vectors, wherein the one or more vectors comprise:
[0305] (1) a first regulatory element, which is operably linked to a nucleotide sequence encoding the Cas protein or a nucleotide sequence encoding the fusion protein; and
[0306] (2) a second regulatory element, wherein the second regulatory element is operably linked to a nucleotide sequence encoding the guide RNA, wherein the guide RNA comprises:
[0307] (a) a spacer sequence capable of hybridizing with a target sequence of a target nucleic acid, and
[0308] (b) a direct repeat (DR) sequence connected to the spacer sequence and capable of guiding the Cas protein to bind to the guide RNA to form a CRISPR-Cas complex targeting the target sequence;
[0309] Wherein the first regulatory element and the second regulatory element are located on the same or different vectors of the CRISPR-Cas vector system.
[0310] In one embodiment, the first regulatory element or the second regulatory element comprises a promoter, and the promoter comprises one or more of an inducible promoter, a constitutive promoter, or a tissue-specific promoter;
[0311] In one embodiment, the promoter comprises one or more of T7, SP6, T3, CMV, EF1a, SV40, PGK1, human β-actin, CAG, U6, H1, T7, T7lac, araBAD, trp, lac or Ptac;
[0312] In one embodiment, the first regulatory element and the second regulatory element are located on the same or different vectors.
[0313] In one embodiment, the vector comprises a retroviral vector, a lentiviral vector, an adenoviral vector, an adeno-associated viral vector, a herpes simplex vector, or a phagemid vector;
[0314] In one embodiment, the vector comprises a plasmid vector.
[0315] In one embodiment, the target nucleic acid comprises DNA derived from a eukaryotic organism or DNA derived from a prokaryotic organism;
[0316] In one embodiment, the eukaryotic organism includes an animal or a plant;
[0317] In one embodiment, the target nucleic acid comprises non-human mammal DNA, human DNA, insect DNA, bird DNA, reptile DNA, amphibian DNA, rodent DNA, fish DNA, worm DNA, nematode DNA, or yeast DNA;
[0318] In one embodiment, the non-human mammalian DNA comprises non-human primate DNA.
[0319] CRISPR / Cas complex
[0320] The term "CRISPR / Cas complex" refers to a complex formed by the binding of guide RNA, gRNA (guide RNA) or mature crRNA (or guide RNA) to the Cas protein, which includes a co-directional repeat sequence that hybridizes to the guide sequence of the target sequence and binds to the Cas protein, and the complex can recognize and cut the target nucleotide that can hybridize with the guide RNA or mature crRNA.
[0321] Guide RNA (gRNA)
[0322] The terms "guide RNA (gRNA)", "mature crRNA", "crRNA", "guide sequence", "guide RNA" are used interchangeably and have the meanings generally understood by those skilled in the art. In general, the guide RNA may comprise a direct repeat (DR) sequence and a spacer sequence, or may consist essentially of or consist of a direct repeat (DR) sequence and a spacer sequence.
[0323] In some cases, the spacer sequence is any polynucleotide sequence that has sufficient complementarity with the target sequence to hybridize with the target sequence and guide the CRISPR-Cas complex to specifically bind to the target sequence. In one embodiment, when optimally aligned, the degree of complementarity between the spacer sequence and its corresponding target sequence is at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, or at least 99%. The guide sequence comprises a sequence (e.g., a direct repeat (DR) sequence) that has sufficient complementarity with the target nucleic acid sequence to hybridize with the target nucleic acid sequence and guide the sequence-specific binding of the complex to the target nucleic acid sequence.
[0324] It is known in the art that on the basis of sufficient complementarity to function, complete complementarity is not required, and therefore, if necessary, the adjustment of the cleavage efficiency can be achieved by introducing mismatches (e.g., one or more mismatches between the spacer sequence and the target nucleic acid, such as 1 or 2 nucleotide mismatches (including the position of the mismatch along the spacer sequence / target sequence)). For example, if a cleavage rate of less than 100% of the target is desired (e.g., in a cell population), 1 or 2 mismatches between the spacer sequence and the target sequence can be introduced into the spacer sequence.
[0325] In one aspect, the present invention provides a guide RNA, comprising a direct repeat (DR) sequence capable of binding to the Cas protein and a spacer sequence capable of targeting a target sequence.
[0326] In one embodiment, the direct repeat sequence, the direct repeat sequence (Direct Repeat, DR) comprises the sequence shown in SEQ ID NO.5.
[0327] In one embodiment, the 3' end of the direct repeat sequence comprises a stem-loop structure, and further comprises a stem of the stem-loop structure formed by hybridization of a first stem nucleotide chain and a second stem nucleotide chain, and the loop nucleotide chain forms a loop of the stem-loop structure;
[0328] In one embodiment, the direct repeat sequence comprises a nucleotide sequence having at least 80% identity with the nucleotide sequence described in SEQ ID NO.5;
[0329] In one embodiment, the direct repeat sequence comprises a nucleotide sequence having at least 85% or more, more preferably 90% or more, and further preferably 95% or more identity with the nucleotide sequence described in SEQ ID NO.5;
[0330] In one embodiment, the direct repeat sequence comprises the nucleotide sequence described in SEQ ID NO.5.
[0331] In one embodiment, more than 80% of the spacer sequence is complementary to the target nucleic acid;
[0332] In one embodiment, more than 90%, more preferably more than 95%, further preferably more than 99%, and further preferably 100% of the spacer sequence is complementary to the target nucleic acid;
[0333] In one embodiment, the length of the spacer sequence is 18-41 nt, for example 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 nt, more preferably 18 to 27 nucleotides, more preferably 18 to 24 nucleotides, and most preferably 18 to 22 nucleotides.
[0334] In one embodiment, the spacer sequence is 20 nt in length.
[0335] Target nucleic acid
[0336] In the present invention, target nucleic acid is used interchangeably with target sequence or target nucleic acid sequence or target nucleic acid molecule, and refers to a specific nucleic acid comprising a nucleic acid sequence that is fully or partially complementary to the spacer sequence in the guide RNA. "Target sequence" refers to a polynucleotide targeted by the spacer sequence in the guide RNA, such as a sequence complementary to the spacer sequence, wherein the hybridization between the target sequence and the spacer sequence will promote the formation of a CRISPR-Cas complex (including Cas protein and guide RNA). Complete complementarity is not required, as long as there is enough complementarity to cause hybridization and promote the formation of a CRISPR-Cas complex. In some embodiments, the target nucleic acid comprises a non-coding region (e.g., a promoter or terminator). In some embodiments, the target nucleic acid is single-stranded, or double-stranded.
[0337] The target sequence can comprise any polynucleotide, such as DNA. In some cases, the target sequence is located in a cell or outside the cell. In some cases, the target sequence is located in the nucleus, cytoplasm, or organelle (e.g., mitochondria or chloroplast) of the cell.
[0338] The target nucleic acid can be a sequence encoding a gene product (e.g., a protein) or a non-coding sequence (e.g., a regulatory polynucleotide or junk DNA). In some cases, the target sequence should be associated with a protospacer adjacent motif (PAM).
[0339] Donor template
[0340] In the present invention, donor template nucleic acid or donor template are used interchangeably to refer to a nucleic acid molecule that one or more cellular proteins can use to change the structure of the target nucleic acid after the Cas protein described herein changes the target nucleic acid.
[0341] In some embodiments, the donor template nucleic acid is a double-stranded nucleic acid or a single-stranded nucleic acid. In some embodiments, the donor template nucleic acid is linear or circular (e.g., plasmid). In some instances, the donor template nucleic acid is an exogenous nucleic acid molecule. In some instances, the donor template nucleic acid is an endogenous nucleic acid molecule (e.g., chromosome). In some embodiments, the donor template can be used to realize genetic recombination, and the recombination is homologous recombination.
[0342] Cutting
[0343] Cleavage refers to DNA breaks in a target nucleic acid produced by a Cas protein as described herein. In some embodiments, cleavage is a double-stranded DNA break. In some embodiments, cleavage is a single-stranded DNA break.
[0344] In the present invention, the meanings of cleaving a target nucleic acid or modifying a target nucleic acid may overlap. Modifying a target nucleic acid includes not only modification of a single nucleotide, but also insertion or deletion of a nucleic acid fragment.
[0345] Reporter nucleic acid
[0346] Reporter nucleic acid refers to a molecule that can be cut or otherwise deactivated by an activated CRISPR system protein as described herein. Reporter nucleic acid comprises a nucleic acid element that can be cut by a CRISPR protein (e.g., using a single-stranded non-targeted nucleic acid molecule, with different reporter groups or labeling molecules at both ends). The cutting of the nucleic acid element produces a detectable signal. Before cutting, or when the reporter nucleic acid is in an "active" state, the reporter nucleic acid prevents the generation or detection of a positive detectable signal. It will be understood that in certain example embodiments, a minimum background signal can be generated in the presence of an active reporter nucleic acid. A positive detectable signal can be any signal that can be detected using optics, fluorescence, chemiluminescence, electrochemistry, or other detection methods known in the art. For example, in certain embodiments, when a reporter nucleic acid is present, a first signal (i.e., a negative detectable signal) can be detected, which is then converted to a second signal (e.g., a positive detectable signal) after the target molecule is detected and cut or deactivated by an activated CRISPR protein. The reporter nucleic acid can be a single-stranded DNA molecule, a single-stranded RNA molecule, or a single-stranded DNA-RNA hybrid.
[0347] The detection method of the present invention can be used for quantitative detection of target nucleic acid to be detected. The quantitative detection index can be quantified according to the signal strength of the reporter group, such as according to the luminescence intensity of the fluorescent group, or according to the width of the color band.
[0348] Functional domain
[0349] The functional domain herein is taken in its broadest sense, including proteins such as enzymes or factors themselves or having specific functional fragments / domains. Cas proteins (e.g., dCas proteins) are connected / concluded with one or more functional domains, and the functional domains are selected from one or more of localization signals, reporter proteins, Cas protein targeting moieties, DNA binding domains, epitope tags, transcription activation domains, transcription inhibition domains, nucleases, deamination domains, methylases, demethylases, transcription release factors, HDACs, cleavage active polypeptides, and ligases. When more than one functional domain is included, the functional domains may be the same or different.
[0350] Deamination domain
[0351] In the present invention, the deamination domain includes a deaminase (e.g., an adenosine deaminase or a cytidine deaminase) catalytic domain. As used herein, "adenosine deaminase" or "adenosine deaminase protein" refers to a protein, a polypeptide, or one or more functional domains of a protein or polypeptide that is capable of catalyzing a hydrolytic deamination reaction that converts adenine (or the adenine portion of a molecule) into hypoxanthine (or the hypoxanthine portion of a molecule).
[0352] In some embodiments, the adenine-containing molecule is adenosine (A), and the hypoxanthine-containing molecule is inosine (I). The adenine-containing molecule can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
[0353] Adenosine deaminases include, but are not limited to, members of the enzyme family known as adenosine deaminases acting on RNA (ADAR), members of the enzyme family known as adenosine deaminases acting on tRNA (ADAT), and other family members containing adenosine deaminase domains (ADAD). According to the present disclosure, adenosine deaminases are capable of targeting adenine in RNA / DNA and RNA duplexes. In a specific embodiment, adenosine deaminases have been modified to increase their ability to edit DNA in RNA / DNA heteroduplexes of RNA duplexes.
[0354] In some embodiments, the deaminase is a cytidine deaminase. The term "cytidine deaminase" or "cytidine deaminase protein" refers to a protein, a polypeptide, or one or more functional domains of a protein or polypeptide that is capable of catalyzing a hydrolytic deamination reaction that converts cytosine (or the cytosine portion of a molecule) into uracil (or the uracil portion of a molecule). In some embodiments, the cytosine-containing molecule is cytidine (C), and the uracil-containing molecule is uridine (U). The cytosine-containing molecule can be deoxyribonucleic acid (DNA) or ribonucleic acid (RNA).
[0355] Cytidine deaminases include, but are not limited to, members of the enzyme family known as apolipoprotein B mRNA editing complex (APOBEC) family deaminases, activation-induced deaminases (AID), or cytidine deaminase 1 (CDA1). In a specific embodiment, an APOBEC family deaminase is included.
[0356] In some embodiments, the cytidine deaminase comprises a wild-type amino acid sequence of a cytidine deaminase. In some embodiments, the cytidine deaminase comprises one or more mutations in the cytidine deaminase sequence such that the editing efficiency and / or substrate editing preference of the cytidine deaminase is changed according to specific needs.
[0357] Identity
[0358] "Identity" is used to refer to the matching of sequences between two polypeptides or between two nucleic acids. "Identity" means the percentage of the number of identical residues between the polypeptide or nucleic acid sequences to the total number of residues, and the calculation of the total number of residues is determined based on the type of mutation. Mutation types include insertions (extensions) at either or both ends of the sequence, deletions (truncations) at either or both ends of the sequence, substitutions / alternations of one or more amino acids / nucleotides, insertions within the sequence, and deletions within the sequence.
[0359] Taking a polypeptide sequence as an example, if the mutation type is one or more of the following: substitution / replacement of one or more amino acids / nucleotides, insertion within the sequence, and deletion within the sequence, the total number of residues is calculated as the larger of the molecules being compared. If the mutation type also includes an insertion (extension) at either or both ends of the sequence or a deletion (truncation) at either or both ends of the sequence, the number of amino acids inserted or deleted at either or both ends (for example, the number of insertions or deletions at both ends is less than 20) is not included in the total number of residues. When calculating the percent identity, the sequences being compared are aligned in a manner that produces the maximum match between the sequences, and gaps in the alignment (if any) are resolved by a specific algorithm. The same applies to the calculation of nucleotide identity.
[0360] Carrier
[0361] A vector is a nucleic acid molecule that is capable of transporting another nucleic acid molecule to which it has been linked.
[0362] Vectors include, but are not limited to, single-stranded, double-stranded, or partially double-stranded nucleic acid molecules; nucleic acid molecules including one or more free ends, or no free ends (e.g., circular); nucleic acid molecules including DNA, RNA, or both; and other various polynucleotides known in the art. Vectors can be introduced into host cells by transformation, transduction, or transfection so that the genetic material elements they carry are expressed in the host cells. A vector can be introduced into a host cell to produce transcripts, proteins, or peptides, including proteins, fusion proteins, isolated nucleic acid molecules, etc. as described herein (e.g., CRISPR transcripts, such as nucleic acid transcripts, proteins, or enzymes). A vector can contain a variety of elements that control expression, including, but not limited to, promoter sequences, transcription start sequences, enhancer sequences, selection elements, and reporter genes. The vector may also contain a replication initiation site.
[0363] Vectors include plasmids and viral vectors, wherein the plasmid refers to a circular double-stranded DNA loop into which other DNA fragments can be inserted, for example, by standard molecular cloning techniques. Viral vectors, wherein virally derived DNA or RNA sequences are present in vectors for packaging viruses, and viruses include, for example, retroviruses, replication-defective retroviruses, adenoviruses, replication-defective adenoviruses, and adeno-associated viruses. Viral vectors also include polynucleotides carried by viruses for transfection into a host cell. Some vectors (for example, bacterial vectors and episomal mammalian vectors with bacterial replication origins) can replicate autonomously in the host cells into which they are introduced.
[0364] Other vectors (e.g., non-episomal mammalian vectors) are integrated into the genome of the host cell after introduction into the host cell, and are replicated together with the host genome. Moreover, some vectors are capable of directing the expression of genes to which they are operably linked. Such vectors are referred to as "expression vectors."
[0365] In some embodiments, the vector (e.g., a viral vector or a non-viral vector, such as a lentiviral vector or a plasmid) can be delivered to the target tissue by, for example, intramuscular injection, intravenous administration, transdermal administration, intranasal administration, oral administration, or mucosal administration. The above delivery can be carried out via a single dose or multiple doses. It will be appreciated by those skilled in the art that the actual dose to be delivered herein can vary to a large extent according to a variety of factors, including but not limited to vector selection, target cells, organisms, tissues, the general condition of the subject to be treated, the degree of transformation / modification sought, the route of administration, the mode of administration, and the type of transformation / modification sought.
[0366] Regulatory elements
[0367] Herein, "regulatory elements" include promoters, enhancers, internal ribosome entry sites (IRES) and other expression control elements (e.g., transcription termination signals, such as polyadenylation signals, poly-U sequences), which are described in detail in Goeddel, GENE EXPRESSION TECHNOLOGY: METHODS IN ENZYMOLOGY 185, Academic Press, San Diego, Calif (1990). In some cases, regulatory elements include those sequences that direct the constitutive expression of a nucleotide sequence in many types of host cells and those sequences (e.g., tissue-specific regulatory sequences) that direct the nucleotide sequence to be expressed only in certain host cells. Tissue-specific promoters can mainly direct expression in the desired tissue of interest, such as muscle, neuron, bone, skin, blood, specific organs (e.g., liver, pancreas) or special cell types (e.g., lymphocytes). In other cases, regulatory elements can also direct expression in a timing-dependent manner (e.g., in a cell cycle-dependent or developmental stage-dependent manner), which may or may not be tissue- or cell-type-specific.
[0368] The term "promoter" refers to a non-coding nucleotide sequence that is located upstream of a gene and can initiate downstream gene expression. A constitutive promoter is a nucleotide sequence that, when operably linked to a polynucleotide that encodes or limits a gene product, will result in the production of a gene product in the cell under most or all physiological conditions of the cell. An inducible promoter refers to a promoter that selectively expresses a coding sequence or functional RNA in response to the presence of endogenous or exogenous stimuli, such as by responding to chemical compounds (chemical inducers), or to environmental, hormone, chemical, and / or developmental signals. Inducible or regulated promoters include promoters that are induced or regulated, for example, by light, heat, stress, flooding or drought, salt stress, osmotic stress, plant hormones, wounds, or chemicals (such as ethanol, abscisic acid (ABA), jasmonates, salicylic acid, or safeners).
[0369] Host cells
[0370] As used herein, "host cell" refers to a eukaryotic cell (e.g., an animal cell, a plant cell, a fungal cell, etc.), a prokaryotic cell (e.g., some microbial cells, Escherichia coli, Bacillus subtilis, etc.), or a cell from a multicellular organism cultured as a unicellular entity (e.g., a cell line), which serves as a recipient of nucleic acid (e.g., an expression vector) and includes the descendants of the original cell that has been genetically modified by the nucleic acid.
[0371] It is understood that the progeny of a single cell may not necessarily have completely the same morphology or genome, etc. as the original parent cell due to natural, accidental, or deliberate mutation. A "recombinant host cell" (also called a "genetically modified host cell") is a host cell into which a heterologous nucleic acid, such as an expression vector, has been introduced.
[0372] Those skilled in the art will appreciate that the design of the expression vector may depend on factors such as the choice of the host cell to be transformed, the level of expression desired, and the like.
[0373] In another aspect, the present invention also provides a host cell or its progeny, wherein the host cell comprises the aforementioned Cas protein, or the aforementioned fusion protein, or the aforementioned polynucleotide, or the aforementioned vector system, or the aforementioned CRISPR-Cas system, or the aforementioned composition.
[0374] In one embodiment, the host cell comprises a non-human mammal, human, insect, bird, reptile, amphibian, rodent, fish, worm, nematode, or yeast cell.
[0375] In one aspect, the present invention also provides a multicellular organism, comprising the aforementioned cell or its progeny.
[0376] In one embodiment, the multicellular organism is an animal model or a plant model for a relevant disease.
[0377] NLS
[0378] NLS refers to "nuclear localization sequence" or "nuclear localization signal", which refers to an amino acid sequence that promotes protein entry into the nucleus. Nuclear localization sequences are known in the art (e.g., Plank et al. International PCT Application PCT / EP2000 / 011690 filed on November 23, 2000 and published as WO / 2001 / 038547 on May 31, 2001) and are incorporated herein by reference for their disclosure of exemplary nuclear localization sequences. In other embodiments, the NLS is an optimized NLS, such as described in Koblan et al., Nature Biotech.2018doi:10.1038 / nbt.4172. In some embodiments, the NLS comprises the following amino acid sequence: KRTADGSEFESPKKKRKV (SEQ ID NO.38), AVKRPAATKKAGQAKKKKLD (SEQ ID NO.39), KRPAATKKAGQAKKKK (SEQ ID NO.40), KKTELQTTNAENKTKKL (SEQ ID NO.41), KRGINDRNFWRGENGRKTR (SEQ ID NO.42), RKSGKIAAIVVKRPRK (SEQ ID NO.43), PKKKRKV (SEQ ID NO.44) or MDSLLMNRRKFLYQFKNVRWAKGRRETYLC (SEQ ID NO.45).
[0379] Operatively connected
[0380] "Operably linked" means that the target nucleotide sequence is linked to the regulatory elements in a manner that allows the nucleotide sequence to be expressed (e.g., in an in vitro transcription / translation system or in a host cell when the vector is introduced into the host cell). Advantageous vectors include lentiviruses and adeno-associated viruses, and the type of these vectors can also be selected to target specific types of cells.
[0381] Complementarity
[0382] "Complementarity" refers to the ability of one nucleic acid sequence to form one or more hydrogen bonds with another nucleic acid sequence by means of traditional Watson-Crick or other non-traditional types. The percentage of complementarity represents the percentage of residues in one nucleic acid molecule that can form hydrogen bonds (e.g., Watson-Crick base pairing) with another nucleic acid sequence (e.g., 5, 6, 7, 8, 9, 10 out of 10 are complementary, then the percentage of complementarity is 50%, 60%, 70%, 80%, 90% and 100%). "Complete complementarity" means that all consecutive residues of one nucleic acid sequence form hydrogen bonds with the same number of consecutive residues in another nucleic acid sequence. "Substantially complementary" refers to a degree of complementarity of at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, 97%, 98%, 99% or 100% over a region of 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 35, 40, 45, 50 or more nucleotides, or to two nucleic acids that hybridize under stringent conditions.
[0383] The term "stringent conditions" in relation to hybridization refers to conditions under which a nucleic acid having complementarity to a target sequence predominantly hybridizes to the target sequence and substantially does not hybridize to non-target sequences. Stringent conditions are generally sequence-dependent and depend on many factors. In general, the longer the sequence, the higher the temperature at which the sequence specifically hybridizes to its target sequence.
[0384] "Hybridization" refers to a reaction in which one or more polynucleotides react to form a complex that is stabilized via hydrogen bonding of the bases between the nucleotide residues. The complex may comprise two strands forming a duplex, three or more strands forming a multi-stranded complex, a single self-hybridizing strand, or any combination of these. A hybridization reaction may constitute a step in a broader process such as the initiation of PCR, or cleavage of a polynucleotide by an enzyme. Sequences that are capable of hybridizing to a given sequence are referred to as the "complement" of the given sequence.
[0385] Hybridization of the target sequence with the gRNA means that at least 60%, 65%, 70%, 75%, 80%, 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 100% of the nucleic acid sequences of the target sequence and the gRNA can hybridize to form a complex; or represents that at least 12, 15, 16, 17, 18, 19, 20 or more bases of the nucleic acid sequences of the target sequence and the gRNA can complementarily pair and hybridize to form a complex.
[0386] Express
[0387] Nucleic acid expression includes one or more of generation of an RNA template from a DNA sequence (e.g., transcription), processing of the RNA transcript (e.g., by splicing, editing, 5' cap formation, and / or 3' end processing), translation of the RNA into a polypeptide or protein, or post-translational modification of the polypeptide or protein.
[0388] deliver
[0389] "Delivery" refers to providing an entity (such as a drug) to a destination, for example, the components of the CRISPR-Cas system / composition of the present invention can be delivered in various forms, such as a combination of DNA / RNA or RNA / RNA or protein RNA. For example, the Cas protein can be delivered as a polynucleotide encoding DNA or a polynucleotide encoding RNA or as a protein.
[0390] In one aspect, the present invention also provides a delivery system, comprising the Cas protein or the fusion protein, or the polynucleotide, or the CRISPR-Cas composition.
[0391] In one embodiment, the delivery system further comprises a delivery vehicle, and the delivery vehicle comprises nanoparticles, liposomes, exosomes, microbubbles, a gene gun or an electroporation device.
[0392] In addition, when the delivery object is a plant cell, a method such as cell penetrating peptide (CPP) delivery is also adopted. For example, in a specific embodiment, Cas protein and / or at least one guide RNA is coupled to one or more CPPs, so as to effectively transport the CPP coupled with Cas protein and / or guide RNA into the plant cell (e.g., protoplast). CPP has a short peptide of less than 35 amino acids, which is derived from a protein or derived from a chimeric sequence, and can transport biomolecules across the cell membrane in a non-receptor-dependent manner. CPP can be a cationic peptide, a peptide with a hydrophobic sequence, an amphipathic peptide, a peptide rich in proline and an antimicrobial sequence, and a chimeric or dichotomous peptide. CPP can penetrate the biomembrane, and thus trigger different biomolecules to move across the cell membrane into the cytoplasm, and can improve their intracellular pathways, and thus promote the interaction between biomolecules and targets.
[0393] Exemplary, CPPs include Tat (a nuclear transcription activator protein required for viral replication by HIV type 1), penetratin, Kaposi fibroblast growth factor (FGF) signal peptide sequence, integrin β3 signal peptide sequence, poly-arginine peptide Arg sequence, guanine-rich molecular transporter, sweet arrow peptide, etc.
[0394] Connectors
[0395] Herein, "linker" refers to a chemical group or molecule that connects two molecules or parts, such as two domains of a fusion protein, such as a Cas enzyme and a deaminase. In some connection modes, the linker is located between or flanking two groups, molecules or other parts and connects the two by a covalent bond.
[0396] In certain embodiments, the joint is a linear polypeptide formed by connecting amino acids or multiple amino acid residues through peptide bonds. In certain embodiments, the joint is an organic molecule, a group, a polymer or a chemical moiety. The length and type of the joint can be designed as needed. In certain embodiments, the joint can select an artificially synthesized amino acid sequence or a naturally occurring peptide sequence.
[0397] Detection
[0398] In one aspect, the present invention also provides a method for targeting and editing a target nucleic acid, the method comprising contacting the target nucleic acid with any one of the aforementioned CRISPR-Cas systems or compositions.
[0399] In one aspect, the present invention also provides a method for non-specifically degrading single-stranded DNA after recognizing a target nucleic acid, the method comprising contacting the target nucleic acid with the aforementioned CRISPR-Cas composition.
[0400] In one aspect, the present invention also provides a method for targeting a non-spacer complementary strand of a double-stranded target nucleic acid and causing a nick therein after recognizing a spacer complementary strand of the double-stranded target nucleic acid, the method comprising contacting the double-stranded target nucleic acid with the aforementioned CRISPR-Cas system or composition.
[0401] In one aspect, the present invention also provides a method for targeting and cleaving a double-stranded target nucleic acid, the method comprising contacting the double-stranded target nucleic acid with the aforementioned CRISPR-Cas system or composition.
[0402] In one embodiment, the non-spacer sequence complementary strand of the double-stranded target nucleic acid is nicked before the spacer complementary strand of the double-stranded DNA is nicked.
[0403] In one aspect, the present invention also provides a method for specifically editing a double-stranded nucleic acid, the method comprising contacting the following under sufficient conditions and for a sufficient amount of time,
[0404] (1) the aforementioned Cas protein or fusion protein, another enzyme having sequence-specific nicking activity, and the guide RNA, wherein the guide RNA guides the Cas protein or the fusion protein to produce a nick on the relative strand relative to the activity of the other sequence-specific nicking enzyme; and (2) the double-stranded nucleic acid; the method results in the formation of a double-strand break.
[0405] In one aspect, the invention also provides a method of editing a double-stranded nucleic acid, the method comprising contacting the following under sufficient conditions and for a sufficient amount of time:
[0406] (1) the aforementioned Cas protein, or fusion protein, and a fusion protein of a protein domain having DNA modification activity, and the RNA guide targeting the double-stranded nucleic acid; and (2) the double-stranded nucleic acid;
[0407] The Cas protein of the fusion protein is modified to nick the non-target strand of the double-stranded nucleic acid.
[0408] In one embodiment, the two strands of the double-stranded nucleic acid are cleaved at different sites, resulting in staggered cleavage.
[0409] In one embodiment, both strands of the double-stranded nucleic acid are cleaved at the same site, resulting in a blunt double-strand break.
[0410] In one aspect, the present invention also provides a method for targeting and cleaving a single-stranded target nucleic acid, the method comprising contacting the target nucleic acid with the CRISPR-Cas composition of any one of the preceding claims.
[0411] In one aspect, the present invention also provides a method for inducing a change in a cell state, the method comprising contacting the aforementioned CRISPR-Cas composition with the target nucleic acid in a cell.
[0412] In one embodiment, the cell state comprises apoptosis or dormancy;
[0413] In one embodiment, the cell comprises a eukaryotic cell or a prokaryotic cell;
[0414] In one embodiment, the cell comprises a mammalian cell or a plant pathogenic cell;
[0415] In one embodiment, the cell comprises a cancer cell;
[0416] In one embodiment, the cell comprises an infectious cell or a cell infected by an infectious agent;
[0417] In one embodiment, the cells include virus-infected cells, prion-infected cells;
[0418] In one embodiment, the cell comprises a fungal cell, a protozoan, or a parasite cell.
[0419] In one aspect, the present invention also provides a method for detecting a target nucleic acid in a sample, the method comprising contacting the sample with the aforementioned Cas protein, guide RNA and non-target sequence; detecting a detectable signal generated by the Cas protein cutting the non-target sequence, thereby detecting the target nucleic acid; the non-target sequence does not hybridize with the guide RNA.
[0420] Reagent test kit
[0421] In one aspect, the present invention provides a kit, comprising the aforementioned Cas protein, the aforementioned fusion protein, the aforementioned polynucleotide, the aforementioned CRISPR-Cas composition, and the use of the aforementioned host cell in preparing the kit, wherein the components of the kit are in the same or different containers.
[0422] In one aspect, the present invention also provides a container, comprising the aforementioned kit.
[0423] In one embodiment, the container comprises a sterile container;
[0424] In one embodiment, the container comprises a syringe.
[0425] In some embodiments, the kit also includes instructions for using the kit, such as instructions in more than one language. The kit may also include one or more reagents for use in the process of utilizing one or more of the above components. The reagents may be provided in any suitable container. For example, the kit may provide one or more reaction or storage buffers. The above reagents may be provided in a form (e.g., in a concentrated or lyophilized form) requiring the addition of one or more other components before use; the buffer may be any buffer, including but not limited to sodium carbonate buffer, sodium bicarbonate buffer, borate buffer, Tris buffer, MOPS buffer, HEPES buffer, and combinations thereof. The buffer may have a suitable pH value, for example, may be alkaline. In some embodiments, the pH of the buffer is between about 7-10.
[0426] treat
[0427] "Treatment" refers to treating or curing a subject's condition, delaying the onset of symptoms of a condition, and / or delaying the severity of a condition. The term "subject" includes, but is not limited to, various animals, plants, and microorganisms. Animals include mammals, such as bovines, equines, ovines, swine, canines, felines, lagomorphs, rodents (e.g., mice or rats), non-human primates (e.g., macaques or cynomolgus monkeys), or humans. In certain embodiments, the subject (e.g., a human) suffers from a condition (e.g., a condition caused by a disease-related genetic defect). "Plant" is any differentiated multicellular organism capable of photosynthesis, including crop plants at any maturity or developmental stage.
[0428] In one aspect, the present invention also provides the use of the aforementioned Cas protein, the aforementioned fusion protein, the aforementioned polynucleotide, the aforementioned CRISPR-Cas composition, and the aforementioned host cell in the preparation of a medicament for treating a condition or disease in a subject in need thereof.
[0429] In one embodiment, the use comprises administering the CRISPR-Cas composition to the subject or to an ex vivo cell of the subject;
[0430] In one embodiment, the spacer sequence is complementary to at least 15 nucleotides of the target nucleic acid associated with the condition or disease, and the Cas protein or the fusion protein cleaves the target nucleic acid;
[0431] In one embodiment, the condition or disease comprises cancer or an infectious disease;
[0432] In one embodiment, the cancer comprises one or more of Wilms tumor, Ewing sarcoma, neuroendocrine tumor, glioblastoma, neuroblastoma, melanoma, skin cancer, breast cancer, colon cancer, rectal cancer, prostate cancer, liver cancer, kidney cancer, pancreatic cancer, lung cancer, biliary tract cancer, cervical cancer, endometrial cancer, esophageal cancer, gastric cancer, head and neck cancer, medullary thyroid cancer, ovarian cancer, glioma, lymphoma, leukemia, myeloma, acute lymphocytic leukemia, acute myeloid leukemia, chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin's lymphoma, non-Hodgkin's lymphoma, or urinary bladder cancer;
[0433] In one embodiment, the condition or disease comprises one or more of cystic fibrosis, pseudohypertrophic muscular dystrophy, Becker muscular dystrophy, alpha-1-antitrypsin deficiency, Pompe disease, myotonic dystrophy, Huntington disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, frontotemporal dementia, hereditary chronic kidney disease, hyperlipidemia, hypercholesterolemia, Leber's congenital amaurosis, sickle cell disease, hypercholesterolemia, transthyretin amyloidosis, or beta thalassemia;
[0434] In one embodiment, the infectious agent of the infectious disease comprises one or more of human immunodeficiency virus, herpes simplex virus-1 or herpes simplex virus-2.
[0435] The main advantages of the present invention include:
[0436] (a) The present invention discovers a new Cas protein for the first time. The Cas protein of the present invention has very good gene editing activity, can effectively edit or cut the target gene, and can effectively treat the symptoms or diseases of a subject in need (for example, one or more of cystic fibrosis, pseudohypertrophic muscular dystrophy, Becker muscular dystrophy, α-1-antitrypsin deficiency, Pompe disease, myotonic dystrophy, Huntington's disease, fragile X syndrome, Friedreich's ataxia, amyotrophic lateral sclerosis, frontotemporal dementia, hereditary chronic kidney disease, hyperlipidemia, hypercholesterolemia, Leber's congenital amaurosis, sickle cell disease, hypercholesterolemia, transthyretin amyloidosis or β-thalassemia).
[0437] (b) The Cas protein of the present invention is a brand-new Cas enzyme, which exhibits good nuclease activity in vivo and in vitro and has broad application prospects.
[0438] (c) Compared with the Cas enzymes disclosed in the prior art, the editing efficiency of the Cas protein of the present invention is advantageous, providing more options for base editing tools.
[0439] (d) The base editor constructed by the Cas enzyme disclosed in the present invention can effectively perform base editing and has potential application prospects.
[0440] The present invention will be further described below in conjunction with specific examples. It should be understood that these examples are intended to illustrate the present invention only and are not intended to limit the scope of the present invention. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as those described in Sambrook et al., Molecular Cloning: A Laboratory Manual (New York: Cold Spring Harbor Laboratory Press, 1989), or under conditions recommended by the manufacturer. Unless otherwise indicated, percentages and parts are weight percentages and weight parts.
[0441] Unless otherwise specified, the reagents and materials in the examples of the present invention are all commercially available products.
[0442] Example 1 Acquisition of Cas protein
[0443] The inventors analyzed the uncultured metagenome and identified a new Cas protein through de-redundancy, protein clustering, etc. The Blast analysis results showed that the sequence identity of the Cas protein was low with the reported Cas proteins, and it was named CasY7 in the present invention.
[0444] The amino acid sequence of the above-mentioned CasY7 protein is shown in SEQ ID NO.1, and its nucleotide sequence after human codon optimization is shown in SEQ ID NO.2.
[0445] The direct repeat (DR) sequence of the guide RNA corresponding to the above CasY7 protein was analyzed, and the results showed that:
[0446] The DNA sequence encoding the direct repeat (DR) sequence of the guide RNA corresponding to the CasY7 protein is:
[0447] CAAGTTGAATCCGTCTATAACTGACGG (SEQ ID NO: 5).
[0448] The inventors used RNAfold to further analyze the RNA secondary structure of the DR sequence in the pre-crRNA. The analysis results are as follows Figure 2 As shown. Analysis found that the PAM corresponding to CasY7 is 5'-TTN, and N is A / T / C / G. The sgRNA (also known as crRNA) sequence of the CasY7 protein consists of a spacer sequence and a direct repeat (DR) sequence.
[0449] After identification, CasY7 of the present invention belongs to the Cas12 protein family.
[0450] Example 2. Verification of Cas protein cleavage activity
[0451] 1. Plasmid construction
[0452] (1) The TTR gene was taken as the target, and a spacer (spacer1) sequence was designed based on the target sequence of the target gene TTR gene: GCATCTCCCCATTCCATGAG (SEQ ID NO. 6).
[0453] According to the DR sequences of CasY7 protein and LbCpf1 protein, the sgRNA sequence targeting the TTR target gene was designed. For details, see the table below:
[0454]
[0455]
[0456] According to the needs of vector expression, T7 promoter and rrnB T2 terminator were added to the 5' and 3' ends of the sgRNA sequences of CasY7 and LbCpf1 to obtain the CasY7-sgRNA1 expression fragment sequence:
[0457] The single underlined sequence part is the CasY7DR sequence, the double underlined sequence part is the spacer sequence, the italic sequence part is the T7 promoter, the wavy underlined sequence part is the rrnB T2 terminator sequence, the linker sequence is between the spacer sequence and the rrnB T2 terminator sequence, the dotted sequence part is the MfeI restriction site, the bold sequence part is the MluI restriction site, and CACCG is the linker.
[0458] In the same way, synthesize the LbCpf1-sgRNA1 expression fragment sequence:
[0459] The single underlined sequence is the LbCpf1DR sequence, the double underlined sequence is the spacer sequence, the italic sequence is the T7 promoter, the wavy underlined sequence is the rrnB T2 terminator sequence, the linker sequence is between the spacer sequence and the rrnB T2 terminator sequence, the dotted sequence is the MfeI restriction site, the bold sequence is the MluI restriction site, and CACCG is the linker.
[0460] To protect the integrity of the sequence, AGC was introduced at the 5' end and ATA was introduced at the 3' end as protective bases when synthesizing the CasY7-sgRNA expression fragment sequence and the LbCpfl-sgRNA expression fragment sequence.
[0461] (2) The CasY7 protein encoding nucleotide sequence (as shown in SEQ ID NO. 2) fragment was synthesized by Suzhou Hongxun Biotechnology Co., Ltd., and the synthesized CasY7 protein encoding nucleotide sequence fragment was constructed into the ABE8e plasmid (Addgene, Plasmid #138489) 466-5160 position to construct a CasY7 recombinant expression plasmid (see the plasmid map) Figure 1 of Figure 1 A).
[0462] The optimized coding nucleotide sequence of LbCpf1 (amino acid sequence such as SEQ ID NO.19) synthesized by Suzhou Hongxun Biotechnology Co., Ltd. (SEQ ID NO.20) was constructed in the same way to obtain the LbCpf1 recombinant expression plasmid (see the plasmid map for details). Figure 1 of Figure 1 B).
[0463] (3) Suzhou Hongxun Biotechnology Co., Ltd. synthesized the sgRNA expression sequence fragments as described in step (1) (CasY7-sgRNA expression fragment sequence and LbCpf1-sgRNA expression fragment sequence), and the sgRNA expression fragment sequence was double-digested (MfeI / MluI) and inserted into the CasY7 recombinant expression plasmid vector that was also double-digested (MfeI / MluI) to obtain the recombinant expression plasmid CasY7+sgRNA expression plasmid expressing CasY7 and sgRNA; the LbCpf1+sgRNA expression plasmid was constructed in the same way.
[0464] (4) Construct a Target plasmid with a targeting sequence. The construction process is as follows:
[0465] Suzhou Hongxun Biotechnology Co., Ltd. synthesized the araC-pBAD-CCDB fragment (SEQ ID NO.18) with the TTR target sequence (SEQ ID NO.6), and inserted the araC-pBAD-CCDB fragment into the 1284-1300 site of the pKESK22 (Addgene, Plasmid #64857) plasmid to obtain the Target plasmid. The sequence of the Target plasmid is shown in SEQ ID NO.4, and the plasmid map is shown in Figure 3 .
[0466] 2. Preparation and transformation of E. coli competent cells
[0467] The Target plasmid was transferred into DH5a competent cells, and the cells were separated and inoculated on LB solid medium containing 50 μg / ml kanamycin sulfate using an inoculation loop. The cells were placed in a biochemical incubator and cultured overnight at 37°C. On the second day, a single colony was picked from the plate and inoculated into a LB liquid medium test tube containing 4 ml 50 μg / ml kanamycin sulfate (Sangon Biotech, A100408-0100), and cultured overnight at 37°C and 200 rpm with shaking. The next day, 4 ml of the bacterial solution was inoculated into a 2L shake flask containing 400 ml 50 μg / ml kanamycin sulfate LB liquid medium, and cultured at 37°C and 200 rpm with shaking for 2-3 hours.
[0468] When the OD600nm value of the bacterial solution reaches 0.3-0.5, take out the shaking bottle and place it on ice for 10-15 minutes. Pour the bacterial solution into a pre-cooled 500ml centrifuge bottle under sterile conditions, centrifuge at 4℃ and 3000rpm for 8 minutes, discard the supernatant, add about 200ml of pre-cooled CaCl2 solution, mix by blowing to suspend the bacteria, and place it in an ice bath for 30 minutes. Then centrifuge the bacterial solution at 4℃ and 3000rpm for 8 minutes, discard the supernatant, add about 8ml of pre-cooled CaCl2 solution, resuspend the bacteria, and divide the resuspended bacteria into 1.5ml EP tubes, 110μl per tube, and store them in an ultra-low temperature refrigerator at -80℃ for use.
[0469] 3. Determination of editing efficiency in E. coli
[0470] Transfer the CasY7+sgRNA expression plasmid and the LbCpf1+sgRNA expression plasmid into the competent cells prepared in step 2. The specific process is as follows:
[0471] (1) Take the competent cells out of -80℃ and quickly insert them into ice. After about 5 minutes, the bacterial block melts, add the CasY7+sgRNA expression plasmid, and then gently mix it by hand at the bottom of the centrifuge tube, and let it stand in ice for 25 minutes. Heat shock in a 42℃ water bath for 45 seconds, quickly return it to ice and let it stand for 2 minutes. Add 900μl of sterile LB medium without antibiotics to the centrifuge tube, mix it and resuscitate it at 37℃ and 220rpm for 60min. Take 100μl of the bacterial solution and spread it on LB agar plates containing 30μg / ml carbenicillin resistance (Sangon Biotechnology, A100358-0001) (referred to as C-LB medium) and LB agar plates containing 30μg / ml carbenicillin resistance and 10mM L-arabinose (Sangon Biotechnology, A610071-0100) (referred to as CL-LB medium). Two LB agar plates were placed upside down in an incubator and cultured overnight at 37°C.
[0472] (2) Detection of editing efficiency in E. coli
[0473] like Figure 3 As shown, the Target plasmid carries a PBAD promoter that can be induced by L-arabinose and a CCDB gene whose expression is regulated by the PBAD promoter. The CCDB gene can express the CCDB toxic protein. The CCDB toxic protein, as a DNA gyrase inhibitor, can lock the complex of DNA gyrase and broken double-stranded DNA, making the DNA gyrase unable to function, and ultimately leading to cell death.
[0474] Based on this, the inventors designed a method for detecting the editing efficiency of E. coli in vivo:
[0475] In the presence of L-arabinose in the culture medium, if the CasY7 protein or the LbCpf1 protein can specifically target the target sequence (SEQ ID NO.6) of the TTR gene on the Target plasmid under the guidance of sgRNA and play a cutting role, the regulatory expression pathway of the CCDB toxic protein by the PBAD promoter is cut off, and the host cell survives because it does not produce ccdB toxic protein; conversely, if the CasY7 protein or the LbCpf1 protein cannot specifically target the TTR target sequence on the Target plasmid, the host cell Escherichia coli will die because the L-arabinose-induced PBAD promoter regulates the CCDB gene to express the CCDB toxic protein.
[0476] Therefore, the editing efficiency of the CasY7 protein in targeted cleavage of the TTR target gene in Escherichia coli can be calculated based on the ratio of the number of bacterial clones on the CL-LB medium to the number of bacterial clones on the C-LB medium in step (2).
[0477] The results are as follows Figure 4 As shown, after counting the number of E. coli clones and calculating the ratio, it was found that the editing efficiency of CasY7 protein was 45.5%. In addition, the editing efficiency of LbCpf1 protein was 11.1%. The editing efficiency of CasY7 protein was significantly higher than that of LbCpf1 protein.
[0478] Example 3 Editing efficiency detection in HEK293T cells
[0479] 1. Construction of TTR-sgRNA expression plasmid
[0480] (1) Design the TTR-sgRNA sequence according to the target sequence of the TTR gene (Target-TTR-spacer2) tagagaagggatatacaaagtg (SEQID NO.11), and synthesize oligonucleotides (oligos):
[0481] CasY7-TTR-sgRNA2 sequence: CAAGTTGAATCCGTCTATAACTGACGG tagaagggatatacaaagtg (SEQ ID NO. 12), the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0482] LbCpf1-TTR-sgRNA2 sequence:
[0483] TAATTTCTACTAAGTGTAGAT tagaagggatatacaaagtg (SEQ ID NO. 13), the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0484] (2) Add a CACC sequence to the 5' end of the upstream sequence of TTR-sgRNA, add an AAAA sequence to the 5' end of the downstream sequence, and synthesize oligos. The specific sequences are as follows:
[0485]
[0486] After the synthesis of the upstream and downstream primers of the aforementioned TTR-sgRNA, annealing was performed using a preset program (95°C, 5 min; 95°C-85°C at -2°C / s; 85°C-25°C at -0.1°C / s; maintained at 4°C), and then the annealing product was ligated to the PHK09T vector linearized by BsmBI (NEB, #R0580L). The sequence of the PHK09T vector is shown in SEQ ID NO.3, and the plasmid map is shown in Figure 5 .
[0487] The linearization of PHK09T vector and its ligation with TTR-sgRNA annealing product are as follows:
[0488] First, linearize the PHK09T vector. The linearization system is as follows:
[0489] 3 μg of PHK09T vector; 6 μL of buffer (NEB: R0539L); 2 μL of BsmBI; make up to 60 μL with ddH2O, and digest at 50°C overnight.
[0490] TTR-gRNA annealing product and linearized vector connection system:
[0491] 1 μL of T4 ligase buffer (NEB, #M0202L), 20 ng of linearized vector, 5 μL of annealed ol igo fragment, 0.5 μL of T4 ligase (NEB, #M0202L), ddH2O was added to make up to 10 μL, and ligated at 16°C overnight to obtain CasY7-TTR-sgRNA expression plasmid and LbCpf1-TTR-sgRNA expression plasmid.
[0492] (3) The CasY7-TTR-sgRNA expression plasmid and the LbCpf1-TTR-sgRNA expression plasmid obtained in step (2) were respectively transferred into Escherichia coli DH5a competent cells (Weidi Biotechnology, DL1001), and the specific steps are as follows:
[0493] Take the DH5α competent cells out of the -80℃ refrigerator and quickly insert them into ice. After 5 minutes, wait for the bacterial block to melt, add the ligation product and gently mix it by hand at the bottom of the centrifuge tube, and let it stand in ice for 25 minutes. Heat shock in a 42℃ water bath for 45 seconds, quickly return to ice and let it stand for 2 minutes. Add 700μl of sterile LB medium without antibiotics to the centrifuge tube, mix well and recover at 37℃, 200rpm for 60 minutes. After centrifugation at 3000rpm for one minute, collect the bacteria, keep about 100μl of supernatant, gently blow and resuspend the bacterial block and apply it to the LB medium with Amp antibiotics. Invert the plate and culture it in a 37℃ incubator overnight. Pick a single colony, shake the positive clone after sequencing confirmation and extract the plasmid (using the endotoxin-free plasmid extraction kit, TIANGEN: DP120-01), then measure the concentration, and store it in a -20℃ refrigerator for later use.
[0494] 2. Cell-level editing efficiency detection
[0495] (1) HEK293T cell culture
[0496] HEK293T cells (purchased from ATCC) were inoculated in DMEM medium (Gibco, 11965092) supplemented with 10% FBS (v / v), containing 1% Penicillin Streptomycin (v / v) (Gibco, 15140122), and cultured in a 37°C cell culture incubator containing 5% CO2. The cells used for transfection were inoculated in a 24-well cell culture plate and cultured the day before. The cells were observed the next day and transfected when the cells grew to a cell density of about 80%.
[0497] (2) CasY7 recombinant expression plasmid (see the plasmid map for details) Figure 1 of Figure 1 A), CasY7-TTR-sgRNA expression plasmid, LbCpf1 recombinant expression plasmid (plasmid map see Figure 1 of Figure 1 B) LbCpf1-TTR-sgRNA expression plasmid and EGFP-C1 (Addgene, Plasmid, #54759) plasmid were transfected into HEK293T cells.
[0498] The amount of plasmids transfected in each well of the 24-well plate is 0.3 μg of nuclease expression plasmid (CasY7 recombinant expression plasmid or LbCpf1 recombinant expression plasmid), 0.3 μg of sgRNA expression plasmid (CasY7-TTR-sgRNA expression plasmid or LbCpf1-TTR-sgRNA expression plasmid), and 0.3 ug of EGFP-C1 plasmid. The specific transfection operation is as follows:
[0499] CasY7 expression plasmid, CasY7-TTR-sgRNA expression plasmid, and EGFP-C1 plasmid were mixed and then washed with 25 μl of Dilute the transfection-specific reduced serum medium (Source Bio, L530KJ), add 2 μl of Lipofectamine 3000 (Invitrogen, L3000015) reagent, mix well by pipetting as reagent A, and let stand for 5 minutes. Dilute and mix the reduced serum medium for transfection (Source Biotechnology, L530KJ) as reagent B and let stand for 5 minutes.
[0500] Mix the above reagents A and B and blow evenly, and let it stand for 20 minutes. After standing, add the mixed reagents dropwise to the 24-well plate cells to be transfected, and return to the 37°C, 5% CO2 incubator for culture. After 6 hours of transfection, replace the culture medium with DMEM containing 10% FBS.
[0501] In the same way, LbCpf1 recombinant expression plasmid, LbCpf1-TTR-sgRNA expression plasmid, and EGFP-C1 plasmid were transfected into HEK293T cells.
[0502] (3) Editing efficiency detection
[0503] After 48 hours of transfection, the expression of EGFP fluorescent protein indicated that the cells were successfully transfected, and the cells with positive EGFP expression were sorted for editing efficiency detection. The cells were subjected to genome extraction (using a genomic DNA extraction kit, TIANGEN, DP304-03). Identification primers were designed according to experimental requirements, and the identification primer sequences used are shown in the following table:
[0504]
[0505]
[0506] Using the genome as a template, the primers in the above table were used to perform PCR amplification on the sequence near the target site. The PCR amplification system is as follows:
[0507] 2×Taq Master Mix (Vazyme, P112-03) 25 μL; Primer-F (TTR-F) (10 pmol / μL) 1 μL; Primer-R (TTR-R) (10 pmol / μL) 1 μL; Template 1 μL; ddH2O to make up to 50 μL.
[0508] The amplified PCR products were used for high-throughput deep sequencing (Qingke Biotechnology Co., Ltd.) or Sanger sequencing (Boshang Biotechnology (Shanghai) Co., Ltd.) to identify the editing efficiency.
[0509] The editing efficiency of CasY7 and LbCpf1 was tested and identified. Figure 6 As shown, in 293T cells, the editing efficiency of CasY7 was 33%, while that of LbCpf1 was only 22%. The editing efficiency of CasY7 was much higher than that of LbCpf1.
[0510] Example 4 Application of CasY7 in base editing
[0511] (1) Acquisition of catalytically inactive CasY7
[0512] In order to obtain dCasY7 without catalytic activity (i.e., losing cleavage activity), the inventors constructed CasY7 mutants with single point mutations of D592A, D643A, E820A, and D992A: D592A-dCasY7, D643-dCasY7, E820A-dCasY7, and D992A-dCasY7. The amino acid sequences of the above mutants are shown in SEQ ID NOs. 47-50, respectively. The specific construction method is as follows:
[0513] The CasY7+sgRNA expression plasmid obtained in step 1 (3) of Example 2 was subjected to point mutation, and the amino acid modification of CasY7 was performed at 4 sites, namely, aspartic acid (Asp, D) at position 592, aspartic acid (Asp, D) at position 643, glutamic acid (Glu, E) at position 820, and aspartic acid (Asp, D) at position 992 of SEQ ID No. 1, and the amino acids at the above sites were mutated to alanine (Ala, A). The codons before and after the mutation of the above amino acids are shown in the following table:
[0514] Amino acid before mutation Codon Amino acid after mutation Codon Aspartic acid (Asp, D) GAC Alanine (Ala, A) GCA Aspartic acid (Asp, D) GAC Alanine (Ala, A) GCA Glutamate (Glu, E) GAG Alanine (Ala, A) GCA Aspartic acid (Asp, D) GAC Alanine (Ala, A) GCA
[0515] Forward and reverse primers were designed and synthesized for the amino acids and their codons in the above table, and then PCR amplification was performed using the CasY7+sgRNA expression plasmid as a template. After amplification, the amplified product was recovered and purified using a universal DNA purification recovery kit (Tiangen Biochemical Technology (Beijing) Co., Ltd., DP214), and the purified product was transformed into Escherichia coli Dh5a competent cells (Weidi Biotechnology, DL1001), cultured at 37°C overnight, and a single clone was picked for sequencing the next day. After sequencing confirmation, the positive clone was shaken and the plasmid (TIANGEN, DP120-01) was extracted and the concentration was determined, and stored in a -20°C refrigerator for later use.
[0516] The obtained recombinant plasmids with point mutations were named: D592A-dCasY7+sgRNA expression plasmid, D643A-dCasY7+sgRNA expression plasmid, E820A-dCasY7+sgRNA expression plasmid, and D992A-dCasY7+sgRNA expression plasmid.
[0517] Then, the constructed D592A-dCasY7+sgRNA expression plasmid, D643A-dCasY7+sgRNA expression plasmid, E820A-dCasY7+sgRNA expression plasmid, and D992A-dCasY7+sgRNA expression plasmid were respectively subjected to in vivo editing efficiency detection in Escherichia coli. The detection method and calculation method were the same as steps 2 and 3 of Example 2. The experimental results are shown in Figure 7 As shown, by counting the number of Escherichia coli clones and calculating the ratio, it is believed that D592A-dCasY7, D643A-dCasY7, E820A-dCasY7, and D992A-dCasY7 have lost their catalytic activity (cleavage activity), that is, the point mutations of D592A, D643A, E820A, and D992A cause the CasY7 protein to lose its cleavage activity.
[0518] 2. Detection of base editing efficiency at the cellular level
[0519] (1) Construction of CasY7-TTR-sgRNA3 and CasY7-TTR-sgRNA4 plasmids
[0520] Design sgRNA according to the target sequence of the TTR gene: CasY7-TTR-sgRNA3, CasY7-TTR-sgRNA4 sequences, and synthesize oligonucleotides (oligos):
[0521] CasY7-TTR-sgRNA3:
[0522] CAAGTTGAATCCGTCTATAACTGACGG tatatcccttctacaaattc(SEQ ID NO.23);
[0523] CasY7-TTR-sgRNA4:
[0524] CAAGTTGAATCCGTCTATAACTGACGG gtgtctatttccactttgta (SEQ ID NO. 24), wherein the underlined sequence is the DR sequence, and the rest of the sequence is the spacer sequence.
[0525] (2) Add a CACC sequence to the 5' end of the upstream sequence of each sgRNA, and add an AAAA sequence to the 5' end of the downstream sequence. The specific format is as follows:
[0526]
[0527] According to the method of step 1 of Example 3, the upstream and downstream sequences of CasY7-TTR-sgRNA3 and CasY7-TTR-sgRNA4 were annealed and connected to the PHK09T vector to obtain CasY7-TTR-sgRNA3 expression plasmid and CasY7-TTR-sgRNA4 expression plasmid, which were transferred into Escherichia coli DH5a competent cells for plasmid amplification and culture. After correct sequencing and concentration determination, they were stored for later use.
[0528] (3) Construction of base editor plasmid (using 005V1-10-3 as an example)
[0529] The adenosine deaminase catalytic domain selected by the inventors is selected from the mutant of the amino acid sequence shown in SEQ ID NO: 31 (named 005V1-10-3): Q148G+Q149M+P150R, the amino acid sequence of the mutant is shown in SEQ ID NO.32, and the nucleotide sequence encoding the deaminase 005V1-10-3 is shown in SEQ ID NO.33. The base editor fusion protein composed of the deaminase 005V10-3 and CasY7 protein was constructed by homologous recombination. The specific operation is as follows:
[0530] First, Suzhou Hongxun Biotechnology Co., Ltd. synthesized the 005V1-10-3 nucleotide fragment with homology arm sequence and linker:
[0531] The bold part is the 005V1-10-3 nucleotide sequence, the italic part is the left and right homology arm regions, and the wavy line part is the linker sequence.
[0532] The D992A-dCasY7+sgRNA expression plasmid obtained in step (1) was subjected to PCR amplification for linearization to obtain a linearized expression vector. The primers used are shown in the following table:
[0533] Primer name specific sequence D992A-dCasY7-F GCCACGAAGACCATCGTGAG(SEQ ID NO:35) D992A-dCasY7-R Gactttccgcttcttctttgg(SEQ ID NO:36)
[0534] The nucleotide fragment of 005V1-10-3 with homology arm sequence and linker (SEQ ID NO: 34) and D992A-dCasY7+sgRNA linearized expression vector were homologously recombined, and Gibson Assembly Master Mix (NEB, E2611S) was used for reaction. After the reaction, the ligation product was transformed into Escherichia coli DH5a competent cells (Weidi Biotechnology, DL1001). The specific process is as follows:
[0535] After taking out the DH5α competent cells from the -80℃ refrigerator, quickly insert them into ice. After 5 minutes, wait for the bacterial block to melt, add the ligation product and gently mix it by hand at the bottom of the centrifuge tube, and let it stand in ice for 25 minutes. Heat shock in a 42℃ water bath for 45 seconds, quickly put it back into ice and let it stand for 2 minutes. Add 700μl of sterile LB medium to the centrifuge tube, mix it and recover it at 37℃, 200rpm for 60 minutes. Centrifuge at 5000rpm for one minute to collect the bacteria, keep about 100μl of supernatant, gently blow and resuspend the bacterial block and apply it to the LB medium with Amp antibiotics. Invert the plate and place it in a 37℃ incubator overnight. Single colonies were picked, and after sequencing confirmation, the positive clones were shaken and the base editor plasmid was extracted using an endotoxin-free plasmid extraction kit (TIANGEN: DP120-01). The concentration was then measured and stored in a -20°C refrigerator for later use. The nucleotide sequence encoding the base editor fusion protein 005V1-10-3-D992A-dCasY7 is shown in SEQ ID NO: 37, and the amino acid sequence is shown in SEQ ID NO: 46.
[0536] (4) According to the method of step 2 of Example 3, the base editor plasmid and EGFP-C1 (Addgene, Plasmid #54759) plasmid were co-transfected with CasY7-TTR-sgRNA' and CasY7-TTR-sgRNA" expression plasmids into 293T cells respectively.
[0537] 48 hours after transfection, the expression of EGFP fluorescent protein indicated that the cells were successfully transfected, and the cells with positive EGFP expression were sorted to detect the editing efficiency. The 293T cell genome was extracted using a kit (TIANGEN, DP304-03).
[0538] (5) Perform base editing efficiency detection according to the method of step (3) of Example 3.
[0539] Primers were designed according to experimental requirements. The identification primer sequences used are shown in the following table:
[0540]
[0541]
[0542] The results are as follows Figure 8 In Figure 8 As shown in A and 8B, the base editor composed of D992A-dCasY7 can achieve effective editing at multiple sites. Figure 8 As can be seen from A, effective editing occurs at the +2, +4, +13, +15, +16, and +17 sites of CasY7-TTR-sgRNA', and the editing efficiency at the +13, +15, +16, and +17 sites reaches nearly 10% to nearly 30%.
[0543] from Figure 8 B shows that effective editing occurs at the +7, +13, and +20 sites of "CasY7-TTR-sgRNA", with the base editing efficiency at the +13 site exceeding 10% and the editing efficiency at the +20 site exceeding 15%.
[0544] Sequence information:
[0545]
[0546]
[0547]
[0548]
[0549]
[0550]
[0551]
[0552]
[0553]
[0554]
[0555]
[0556]
[0557]
[0558]
[0559] All documents mentioned in the present invention are cited as references in this application, just as each document is cited as reference individually. In addition, it should be understood that after reading the above teachings of the present invention, those skilled in the art can make various changes or modifications to the present invention, and these equivalent forms also fall within the scope defined by the claims attached to this application.
Claims
1. A Cas protein, characterized in that The protein is selected from the group consisting of: (a) a polypeptide having the amino acid sequence shown in SEQ ID NO: 1; (b) a polypeptide having ≥80%, 81%, 82%, 83%, 84%, 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or 99.5% homology (or identity) with the amino acid sequence of SEQ ID NO: 1, and the polypeptide has the biological function of SEQ ID NO: 1; (c) A derivative polypeptide formed by replacing, deleting or adding one or more (preferably 1-20, more preferably 1-10, and more preferably 1-5) amino acid residues of any one of the amino acid sequences shown in SEQ ID NO: 1, and retaining the biological function of SEQ ID NO:
1.
2. A Cas protein variant, characterized in that The variant is a non-natural protein, and the variant is mutated at one or more core amino acid sites associated with cleavage activity selected from the following group corresponding to SEQ ID NO: 1 in the wild-type Cas protein: Aspartic acid (D) at position 592; and / or Aspartic acid (D) at position 643; and / or Glutamic acid (E) at position 820; and / or Aspartic acid (D) at position 992.
3. A fusion protein, characterized in that Comprising the Cas protein of claim 1 or the Cas protein variant of claim 2; and one or more functional domains.
4. An isolated polynucleotide, characterized in that The polynucleotide encodes the Cas protein according to claim 1, the Cas protein variant according to claim 2, or the fusion protein according to claim 3.
5. An isolated nucleic acid molecule, characterized in that It comprises a sequence selected from the following, or consists of a sequence selected from the following: (i) the sequence shown in SEQ ID NO: 5; (ii) a sequence having one or more base substitutions, deletions or additions (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 base substitutions, deletions or additions) compared to the sequence shown in SEQ ID NO: 5; (iii) a sequence having at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95% sequence identity to the sequence shown in SEQ ID NO:5; (iv) a sequence that hybridizes to the sequence described in any one of (i) to (iii) under stringent conditions; or (v) a complementary sequence of the sequence described in any one of (i) to (iii); Furthermore, the sequence described in any one of (ii) to (v) substantially retains the biological function of the sequence from which it is derived; For example, the isolated nucleic acid molecule is RNA; For example, the isolated nucleic acid molecule comprises a direct repeat sequence in a CRISPR / Cas system.
6. A guide RNA (gRNA), characterized in that The guide RNA includes a direct repeat (DR) sequence capable of binding to the Cas protein according to claim 1 and a spacer sequence capable of targeting a target sequence.
7. A composite, characterized in that Include: (i) a protein component selected from the group consisting of the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, or a combination thereof; and (ii) a nucleic acid component selected from the group consisting of the guide RNA of claim 6, a nucleic acid encoding the guide RNA of claim 6, a precursor RNA of the guide RNA of claim 6, a precursor RNA nucleic acid encoding the guide RNA of claim 6, or a combination thereof; Wherein, the protein component and the nucleic acid component are combined with each other to form a complex.
8. A carrier, characterized in that Comprising the polynucleotide according to claim 4 or the nucleic acid molecule according to claim 5.
9. A CRISPR-Cas composition, characterized in that Include: (i) a first component selected from the group consisting of the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, a nucleotide sequence encoding the Cas protein of claim 1 or the Cas protein variant of claim 2 or the fusion protein of claim 3, and any combination thereof; and (ii) a second component, wherein the second component comprises one or more guide RNAs according to claim 6, or a nucleotide sequence encoding the one or more guide RNAs according to claim 6; The guide RNA is capable of forming a complex with the protein, protein variant or fusion protein described in (i).
10. A CRISPR-Cas system, characterized in that Comprising one or more vectors, the one or more vectors comprising: (i) a first nucleic acid, which is a nucleotide sequence encoding the Cas protein of claim 1, the Cas protein variant of claim 2, or the fusion protein of claim 3; optionally, the first nucleic acid is operably linked to a first regulatory element; as well as (ii) a second nucleic acid encoding a nucleotide sequence comprising the guide RNA of claim 6; optionally, the second nucleic acid is operably linked to a second regulatory element; in: The first nucleic acid and the second nucleic acid are present on the same or different vectors; The guide RNA is capable of forming a complex with the protein or fusion protein described in (i).
11. A kit, characterized in that: Comprising one or more components selected from the following: the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the complex of claim 7, the vector of claim 8, the CRISPR-Cas composition of claim 9, or the system of claim 10.
12. A delivery composition, characterized in that Comprising a delivery vector, and one or more selected from the following: the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the complex of claim 7, the vector of claim 8, the CRISPR-Cas composition of claim 9, or the system of claim 10.
13. A host cell, characterized in that Comprising the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the nucleic acid molecule of claim 5, the complex of claim 7, the vector of claim 8, the composition of claim 9, the system of claim 10 or the delivery composition of claim 12.
14. An enzyme preparation, characterized in that The enzyme preparation comprises the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the complex of claim 7, the CRISPR-Cas composition of claim 9, the system of claim 10, or the delivery composition of claim 12.
15. A medicine box, characterized in that: include: A first container, and the complex according to claim 7, the composition according to claim 9, or the system according to claim 10, or a drug containing the complex according to claim 7, the composition according to claim 9, or the system according to claim 10 located in the first container.
16. A medicine box, characterized in that: include: (a1) a first container, and the Cas protein according to claim 1, or the Cas protein variant according to claim 2, or the fusion protein according to claim 3, or a gene encoding the same or an expression vector thereof, or a drug containing the Cas protein according to claim 1, or the Cas protein variant according to claim 2, or the fusion protein according to claim 3, or a gene encoding the same or an expression vector thereof, located in the first container; (b1) an optional second container, and the guide RNA or its expression vector according to claim 6, or a drug containing the guide RNA or its expression vector according to claim 6, located in the second container.
17. A method for targeting and editing a target gene or cleaving a target gene, characterized in that: include: The Cas protein of claim 1, or the Cas protein variant of claim 2, or the fusion protein of claim 3, or the complex of claim 7, or the composition of claim 9, or the system of claim 10, or the delivery composition of claim 12, or the enzyme preparation of claim 14, or the drug kit of claim 15 or 16 is contacted with the target gene, or delivered to a cell containing the target gene, and the target sequence is present in the target gene.
18. A method for inducing a change in cell state, characterized in that: The method comprises contacting the Cas protein of claim 1, or the Cas protein variant of claim 2, or the fusion protein of claim 3, or the complex of claim 7, or the composition of claim 9, or the system of claim 10, or the delivery composition of claim 12, or the enzyme preparation of claim 14, or the drug kit of claim 15 or 16 with a target gene in a cell.
19. A method for altering the expression of a gene product, characterized in that include: The Cas protein of claim 1, or the Cas protein variant of claim 2, or the fusion protein of claim 3, or the complex of claim 7, or the composition of claim 9, or the system of claim 10, or the delivery composition of claim 12, or the enzyme preparation of claim 14, or the kit of claim 15 or 16 is contacted with a nucleic acid molecule encoding the gene product, or delivered to a cell containing the nucleic acid molecule, wherein the target sequence is present in the nucleic acid molecule.
20. A cell or progeny thereof obtained by the method of any one of claims 17 to 19, wherein the cell comprises a modification not present in its wild type.
21. A cell product of the cell of claim 20 or its progeny.
22. An in vitro, ex vivo or in vivo cell or cell line or progeny thereof, characterized in that The cell or cell line or their progeny comprises: the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the complex of claim 7, the vector of claim 8, the CRISPR-Cas composition of claim 9, or the system of claim 10, or the delivery composition of claim 12.
23. Use of the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the nucleic acid molecule of claim 5, the complex of claim 7, the vector of claim 8, the CRISPR-Cas composition of claim 9, the system of claim 10, the kit of claim 11, the delivery composition of claim 12, the enzyme preparation of claim 14, or the kit of claim 15 or 16, characterized in that: For use in the preparation of a medicament or formulation for nucleic acid editing (e.g., gene or genome editing).
24. Use of the Cas protein of claim 1, the protein variant of claim 2, the fusion protein of claim 3, the polynucleotide of claim 4, the complex of claim 7, the vector of claim 8, the CRISPR-Cas composition of claim 9, the system of claim 10, the kit of claim 11, the delivery composition of claim 12, the enzyme preparation of claim 14, or the kit of claim 15 or 16, characterized in that, For use in the preparation of a drug or preparation, the drug or preparation is used for one or more selected from the following groups: (i) ex vivo gene or genome editing; (ii) Detection of single-stranded DNA in vitro; (iii) editing a target sequence in a target locus to modify an organism or non-human organism; (iv) treating a disorder caused by a defect in the target sequence in the target locus; (v) treating a condition or disease in a subject in need thereof.
25. A method for detecting whether a target nucleic acid molecule exists in a sample, characterized in that: The method comprises contacting a sample with the Cas protein of claim 1, the Cas protein variant of claim 2, the fusion protein of claim 3, or the complex of claim 7, the CRISPR-Cas composition of claim 9, or the system of claim 10, the kit of claim 11, or the delivery composition of claim 12, or the enzyme preparation of claim 14, and a non-target sequence, and detecting a detectable signal generated by cleavage of the non-target sequence, thereby detecting the target nucleic acid molecule, wherein the non-target sequence does not hybridize with the guide RNA.
Citation Information
Cited By
Composition for treating hemoglobinopathy and use thereof
WO2026067861A1
HAO1 gene-targeting composition and use thereof
WO2026067862A1
